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Abstract of a thesis submitted in partial fulfilment of the 
requirements for the Degree of Doctor of Philosophy. 
Abstract 
A Molecular Dissection of Neuroinflammation in Ovine Batten Disease 
 
by 
Jarol Zhe Chen 
 
Batten disease (Neuronal ceroid lipofuscinosis, NCL) is a group of devastating 
neurodegenerative diseases that affect children, caused by mutations in a number of genes, 
but the underlying pathogenic mechanisms remain unclear. However, the remarkable 
similarity of pathological features between classical forms of NCL indicates that there may be 
a unique pathway in which NCL proteins play a role. Immunohistochemical investigations of 
ovine Batten disease revealed neuroinflammation preceded neurodegeneration in a 
regionally specific manner. A previous study showed that chronic treatment with an anti-
inflammatory compound minocycline did not inhibit the neuroinflammation, indicating the 
need to understand the specific neuroinflammatory cascade in Batten disease to identify 
likely druggable targets before embarking on drug therapies. A drug screening method is not 
practical in large animals. Thus, a proposed neuroinflammatory cascade was investigated in 
a longitudinal study of CLN6 affected sheep brains. This thesis describes the changes in 
selective neuroinflammatory modulators in this proposed neuroinflammatory cascade 
during the disease progression.  
Selected neuroinflammatory modulators (TNF-α, TGF-β, IL-1β, IL-10, NF-ᴋB, MAPK14, 
JAK/STAT, SOCS3, MnSOD, iNOS, Trk B and BDNF) were investigated by quantitative PCR on 
RNA extracted from different brain regions across ages of disease development (2, 6, 9, 18 
and 24 months). Longitudinal expression of MnSOD and mitochondrial marker (COX IV) was 
also studied by immunohistochemistry on perfusion-fixed brain sections.  
The distribution of MnSOD through the cortical grey matter co-localised to mitochondria and 
became compressed to the boundary between layers I and II and between layers IV and V in 
the affected cortices at 18 and 24 months, following severe neurodegeneration. There was 
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no such compression in the non-degenerating cerebellum and brain stem. Quantification of 
MnSOD and COX IV across the cortical grey matter showed that the expressions were 
reduced at 18 and more so at 24 months, indicating that previous reports of enhanced 
activity are likely to have arisen from unmatched sampling. 
Anti-inflammatory SOCS3 mRNA expression was up-regulated significantly prior to 
neurodegeneration and concurrent to the neuroinflammation, and was accompanied by up-
regulation of its protein expression. It however did not suppress the neuroinflammation. 
Both pro- and anti -inflammatory cytokines (TNF-α, IL-1β, TGF-β, IL-10) were upregulated at 
the initiation of neurodegeneration, at 4-6 months of age, prior to the onset of clinical 
disease and cortical atrophy evident at 10-14 months, whereas the oxidative responsive 
genes SOD2/MnSOD and HO-1 were not. iNOS expression was not found in sheep. NF-ᴋB, 
MAPK14 and JAK/STAT pathway activation followed elevation of cytokines. TrkB expression 
was increased in the advanced disease while BDNF expression remained unchanged. Other 
recently proposed neuroinflammatory modulators (PI3Ks, MT I/II/III, GRN) were also 
investigated. The up-regulation of MT I/II/III followed the increase of cytokines and PI3Ks 
were not changed by the disease. GRN, a mutation in which was thought to cause a new 
form of NCL, showed no causative role in CLN6. 
These results discount the oxidative stress and disruption of blood brain barrier, and reveal 
an uncontrolled neuroinflammatory pathway mediated by irregular cytokine signalling. This 
study highlights the weakness of building scenarios based on observed changes in single 
gene expressions in isolation. Also discussed are the problems associated with the newly 
assigned NCLs that lack a thorough biochemical analyses. A similar study of CLN5 ovine 
Batten disease underway will indicate the generality of these findings. A change of strategy 
is planned to continue these studies. Given the large number of changes observed, a 
transcriptomic approach is probably more appropriate.  
Note: Molecules investigated in this study are fully defined in the abbreviation list. 
Keywords: Batten disease, neuronal ceroid lipofuscinosis, lysosomal storage disorder, animal 
models, sheep, neuroinflammatory cascade, neurodegeneration, oxidative stress 
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There have been six basic subtypes characterised in NCLs, including congenital, infantile, late 
infantile, variant late infantile, juvenile and adult. Each subtype is caused typically by 
particular NCL genes, namely, CLN1, 2, 3, 5, 6, 7, 8 and 10 (Table 1.1). Also, novel NCL-
causing genes have been proposed, being CLN4, 11, 13 and 14 (Table 1.1). Disease causing 
mutations have been documented in the 13 human (NCL) genes 
(http://www.ucl.ac.uk/ncl/mutation.shtml; 2015). 
Table 1.1 Summary of NCL genes, correlated pathology and clinical phenotypes compiled 
from Kousi et al, 2011; Bras et al, 2012; Cotman et al, 2013; Petkau & Leavitt, 2014; Schulz et 
al, 2013; http://www.ucl.ac.uk/ncl/mutation.shtml 
1GROD: granular osmiophilic deposit; CL: curvilinear; FP: fingerprint; RL: rectilinear  
2 gene products are soluble proteins 
3gene products are transmembrane proteins 
 
Gene Locus Protein Encoded Protein 
storage/Ultrastructure 
Subtypes  
CLN1/PPT1 1p32 Palmitoyl protein 
thioesterase (PPT1), soluble2 
Sphingolipid-activator 
proteins A and D (SAP A and 
D)  
GRODs1 
Classic infantile 
CLN2/TPP1 11p15 Tripeptidyl-peptidase I 
(TPP1), soluble2 
Subunit c of mitochondrial 
ATP synthase 
CL1 
Classic late-
infantile 
CLN3 16p12 CLN3, transmembrane3 Subunit c of mitochondrial 
ATP synthase 
FP, CL, RL1 
Classic juvenile 
CLN4/ 
DNAJC5 
? Cysteine-string protein alpha 
(CSPα), soluble2 
CSPα self-aggregates? 
GRODs1 
Adult 
CLN5 13q21.1
-q32 
CLN5, soluble2 Subunit c of mitochondrial 
ATP synthase 
CL, FP, RL1 
Variant late-
infantile 
CLN6 15q21-
q23 
CLN6, transmembrane3 Subunit c of mitochondrial 
ATP synthase 
FP, CL1 
Variant late-
infantile 
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CLN7/MFSD8 4q28.1-
q28.2 
CLN7, transmembrane3 ? 
RL, FP1 
Variant late-
infantile 
CLN8 8p23 CLN8, transmembrane3 ? 
GRODs, CL1 
Variant late-
infantile 
CLN10/CTSD 11p15.5 Cathepsin D, soluble2 SAP A and D 
GRODs1 
Congenital 
CLN11/GRN 17q21 Progranulin, soluble2 TDP-43 
FP1 
Adult? 
CLN12/ATP1
3A2 (canine, 
Belgian 
family?) 
? ATPase type 13A2 
(ATP13A2), transmembrane3 
? 
FP1 
Juvenile? 
CLN13/CTSF ? Cathepsin F (CTSF), soluble2 ? 
FP1 
Adult? 
CLN14/KCTD
7 
? Pottassium channel 
tetramerisation domain 
containing protein type 7 
(KCTD7), soluble2? 
? 
FP, GROD1 
Infantile? 
 
Two distinctive types of genetic products have been predicted; either soluble proteins 
(CLN1, CLN2, CLN5, and CTSD/CLN10) or intramembrane (membrane-bound) proteins (CLN3, 
CLN6, CLN7, and CLN8).  
Among thouse NCLs withthe soluble proteins, infantile NCL, CLN1 and late infantile NCL, 
CLN2 encode the soluble lysosomal enzymes palmitoyl protein thioesterase (PPT1) and 
tripeptidyl peptidase 1 (TPP1), respectively (Vesa et al, 1995; Sleat et al, 1997). A cathepsin D 
(CTSD/CLN10) mutation was found to underlie an ovine congenital NCL, subsequently 
described in humans (Tyynelä et al, 1993; Siintola et al, 2006). The CTSD mutations found are 
associated with reduced enzymatic activity (Steinfeld et al, 2006). CLN5 encodes a soluble 
lysosomal glycoprotein with unknown function (Sleat et al, 2005, 2006, 2007).  
Some NCL associated proteins have been suggested to be membrane-associated. Studies 
have suggested the CLN3 encoded protein may reside in the late endosomal/lysosomal 
membranes and the predicted protein functions may associate with membrane trafficking, 
endocytosis and autophagy as well as regulation of lysosomal pH (Cotman et al, 2002; 
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accumulation of the storage material in lysosome derived organelles localise in nerve cell 
bodies and axonal compartments. As indicated in Table 1.1, the storage bodies have various 
ultrastructures determined by EM, consisting of GRODs, CL, FP and RL, of which images can 
be found in various review papers regarding NCL pathology (Anderson et al, 2013). SAP A 
and D storage seems to correlate predominantly with the GRODs ultrastructure (Anderson et 
al, 2013).  
The subunit c of the mitochondrial ATP synthase was identified to be the main protein 
pathologically accumulated in CLN2, CLN3, CLN5, CLN6, CLN7 and CLN8 NCL forms while the 
SAP A and D, which are small heat-stable glycoproteins required for the hydrolysis of 
sphingolipids in lysosomes, are the main storage materials in the CLN1 and CLN10 forms 
(Animal models: Fearnley et al, 1990; Martinus et al, 1991; Jolly et al, 1994; Pardos et al, 
1994; Palmer et al, 1997; Url et al, 2001; Cook et al, 2002; Katz et al, 2005; Melville et al, 
2005; Frugier et al, 2008; Human NCLs: Palmer et al, 1989a, 1989b, 1992; Hall et al, 1991; 
O’Brien & Kishimoto, 1991; Tyynelä et al, 1993; Kominami et al, 1992; Kida et al, 1993; 
Tyynelä et al, 1997; Herva et al, 2000; Siintola et al, 2006). The storage of other proteins has 
been suggested in recently discovered NCLs (Table 1.1), however the biochemical analyses of 
the protein storage in these forms has not been published.  
The storage bodies are strongly fluorescent and have a maximum excitation range between 
350nm and 370nm and a maximum emission range from between 490 and 520nm (Palmer, 
1987), which is similar to the fluorescent spectra of the material generated in vitro by 
reacting protein and peroxidised lipids (Chio et al, 1969a, b). Hence, the fluorescence of the 
storage bodies was postulated to be derived from the products of lipid peroxidation. 
However, in spite of the “autofluorescent” property of storage bodies, the storage bodies do 
not contain fluorophors and no evidence of lipid peroxidation was found (Palmer et al, 1985, 
1986b, 1988, 1993, 2002; Hall et al, 1989). The fluorescent property may arise from light 
diffracting from the arrangement of the protein aggregates in the storage bodies, due to the 
highly hydrophobic nature of subunit c (Palmer et al, 2002).  
A genetic and a metabolic defect, such as a defective protease were proposed to result in 
the accumulation of subunit c, but these hypothesis were eliminated by characterisation of 
subunit c. The nuclear genes coding for subunit c, P1, P2 and P3 as well as their expression 
were normal in affected sheep (Medd et al, 1993). Mass spectrometry analysis of 
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Progression of neurodegeneration is dependent on the species, the form of NCL and the 
type of mutation. In ovine CLN6, degeneration progresses in a regionally specific manner 
initially evident in the visual cortex, followed by the parieto-occipital and somatosensory 
cortices and progressed to the motor cortex. The degeneration affects the entire cortical 
mantle in advanced near terminal disease. The cerebellum and the subcortical nuclei were 
not affected by the degenerative events in ovine NCL, but cerebellar atrophy occurs in some 
human forms (Oswald et al, 2005; 2008; Goebel & Wisniewski, 2004). There are differences 
between the murine and ovine models and humans in the regional vulnerability of neurons. 
Murine models display vulnerability of the sensory thalamocortical pathways while sheep 
and humans show vulnerability of neurons in the cortex and hippocampus (Palmer et al, 
2013).       
Depletion of the neurons as well as the selective degeneration of neurons underlies the 
progressive regional atrophy. Retinal degeneration occurs primarily in the photoreceptor 
cells and bipolar neurons of the outer nuclear layer, and is less dramatic in other layers of 
retina, whereas the pigment epithelium is relatively well preserved (Graydon & Jolly, 1984). 
Braak and Goebel (1978) reported selective degeneration of the small stellate cells in 
cerebral cortex. Subsequent studies revealed that the pyramidal neurons in cerebral cortical 
layers II to V are vulnerable to neurodegeneration; the precise course depending on the 
form of NCL (Jolly, 1995; Herva et al, 2000; Haltia, 2003; Oswald et al, 2005). In ovine CLN6, 
Nissl staining showed that the neurons between the cerebral cortical layers II to III and V to 
VI are most vulnerable to degeneration, especially the pyramidal neurons in layer III, while 
those in layer V are better preserved (Oswald, 2004).  
The selective degeneration of GABAergic interneurons has been described in human NCL 
patients and animal models of NCLs (Braak & Goebel, 1978; 1979; Cooper et al, 1999; 2003; 
Bible et al, 2004; Pontikis et al, 2004; Kielar et al, 2007; Oswald et al, 2001; 2008; Kay et al, 
2011). In animal models of NCLs, the complex patterns of degeneration in the interneuron 
populations differ between locations (Bible et al, 2004; Pontikis et al, 2004; Kielar et al, 
2007; Oswald et al, 2001; 2008; Kay et al, 2011), suggesting that the cellular location and 
connectivity are the determinants of neuron survival (Oswald et al, 2008). The underlying 
molecular cues and the susceptibility of neurons to such molecular cues may determine the 
neuronal fate. 
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A different mutation, c.184C>T in exon 2, was found to cause a major amino acid exchange 
(p.Arg62Cys) in affected Merino sheep and potentially results in a non-functional protein 
(Tammen et al, 2006). The two distinctively different types of mutations in CLN6 lead to a 
very similar pathological presentation with slightly different disease progression between 
South Hampshires and Merinos (Cook et al, 2002; Personal communications, Imke Tammen 
& Nadia Mitchell, 2015). These are suitable models for human disease, and allow study of 
the impact of different mutations in the same gene could have on the molecular pathology. 
Brains of the CLN6 affected South Hampthires show normal growth from birth to 4 months 
followed by a slow decline (Fig 1.1). The affected animals rarely survive more than 2 years 
naturally (as opposed to a normal sheep potential lifespan of 8 to 10 years at least) and are 
usually euthanised before death for humane reasons. Clinical symptoms become apparent at 
9-12 months, with impaired vision and neurological disturbances and include involuntary 
movements, and circling and confusion (Jolly et al, 1980, Jolly et al, 1982). Pathologies are 
consistent to an NCL, including storage body accumulation in most cell types, 
neuroinflammation, selective neuronal vulnerability and brain atrophy (Jolly et al, 1980, Jolly 
et al, 1982; Mayhew et al, 1985; Oswald et al 2005; 2008). Gross pathology changes are 
restricted to the cerebrum, the size of the affected cerebrum reducing with a thinning of the 
gyri, accompanied by cranial thickening (Jolly et al, 1980, Jolly et al, 1982). The reduction of 
the cerebral cortex occurred progressively and regionally as described before (Section 1.4.3). 
Thinning of the white matter tracts occurs with age and becomes noticeable in the corpus 
callosum adjacent to the lateral ventricle at 19 months (Jolly et al, 1980, Jolly et al, 1982; 
Oswald et al, 2005).  
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Figure 1.1 Brain weight in the CLN6 affected South Hampshires and age matched controls 
(Personal communication, Nadia Mitchell, 2015). The cerebellum is not subjected to 
neurodegeneration, thus the changes in brain weight (g) indicates the atrophy of the 
cerebrum.  
 
Brain atrophy in ovine CLN6 reflects the development of the clinical symptoms. Blindness is 
the most notable clinical feature and is accompanied by occipital cortex atrophy and loss of 
photoreceptors in the retina (Jolly et al, 1989; Mayhew et al, 1985). Accumulation of storage 
material is evident as early as 12 days of age and increases with age throughout the brain 
(section 1.3.1; Oswald et al, 2005). The ultrastructure of the storage bodies demonstrate a 
mixture of appearances including multi-lamellar, finger-print and curvilinear profiles (Palmer 
& Tammen, 2011). The analyses of storage materials of ovine CLN6 showed specific storage 
of subunit c of mitochondrial ATP synthase (Palmer et al, 1986a, 1986b, 1989; Fearnley et al, 
1990). However, the storage of subunit c in most cell types cannot explain the selective and 
regional neuronal loss. In contrast, the regional glial activation accurately predicts regional 
cell loss which follows several months later (Oswald et al, 2005; Kay et al, 2006). 
Glial activation in the CLN6 affected ovine brains has been observed before birth and 
suggests an early onset of pathogenesis during brain development (Kay et al, 2006). The 
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thiols (cysteine methionine) and proteins which possess amino acids like lysine, arginine, 
proline, and threonine that oxidise to form carbonyl groups. Peroxynitrite, generated from 
the interaction of NO and O2-, causes nitrosylation of tyrosine residues and oxidative 
modification of amino acid residues, including cysteine, tryptophan, methione, and 
phenylalanine (Shacter, 2000). For DNA damage, hydroxyl radicals (•OH) react with DNA by 
addition to double bonds of DNA bases, abstraction of H atoms from the methyl groups of 
thymine and each of the C-H bonds of 2’-deoxyribose, resulting in C5-OH and C6-OH radicals 
and the allyl radical. These radicals lead to a series of oxidations of nucleotides (Cooke et al, 
2003).  
Lipid peroxidation is initiated by a hydroxyl radical that attacks a hydrogen from a methylene 
carbon on an unsaturated lipid by removing the hydrogen and leaving an unpaired electron 
on the carbon atom to which the hydrogen was originally attached. The “lipid radical” reacts 
with oxygen and gives rise to a lipid peroxyl radical, which is active to abstract a hydrogen 
from neighbouring methylene of the fatty acid side chain and so on, thus continuing to 
produce more peroxyl radicals that carry on the same peroxidation reaction. This reaction is 
termed the chain reaction of lipid peroxidation (Halliwell & Chirico, 1993). It is proposed that 
the peroxidised lipid could react with proteins to give rise to the “fluorophore”. Lipid 
peroxidation was proposed to cause accumulation of the storage bodies and pathogenesis in 
NCLs because of their lipofuscin-like fluorescence, which was thought arise from the 
products of lipid peroxidation (Chio & Tappel, 1969a; b). The mechanism of lipid 
peroxidation would require the loss of polyunsaturated fatty acids to lipid peroxidation. The 
lipid peroxidation hypothesis was soon disproved, following the development of techniques 
to isolate storage bodies and the identification of the major protein component in the 
storage materials. This is discussed in detail in Chapter 3. 
The brain is thought to be vulnerable to oxidative stress because of its high metabolic rate 
and a lack of capacity of regeneration (Andersen, 2004). The increased oxidative stress was 
thought to cause mitochondrial dysfunction and glutamate excitoxicity in neurons 
(Andersen, 2004; Beal, 2005; Spalloni et al, 2013; Ong et al, 2013; Van Laar et al, 2015). 
1.6.2.1 Mitochondrial dysfunction and oxidative stress 
One of the major ROS producing cell organelles is the mitochondrion, which also produces 
antioxidant enzymes, such as MnSOD, to reduce the potential harm of oxidative stress 
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(Fridovich, 1983; Sayre et al, 1999). Malfunction of mitochondria is proposed to cause a 
reduction in ATP production and calcium buffering and to increase ROS production (Beal, 
2005). Changes of activities of antioxidant enzymes, as a result of mitochondrial dysfunction, 
have been described in Alzheimers (AD) and Parkinsons disease (PD) (Zemlan et al, 1989; 
Sofic et al, 1992; De Leo et al, 1998; Choi et al, 2005). It is postulated that prolonged 
mitochondrial dysfunction triggers apoptosis via the opening of mitochondrial permeability 
transition pore (mPTP) when abnormal oxidative phosphorylation and an increase in 
intracellular Ca2+ takes place, in turn resulting in the release of apoptotic signals such as 
cytochrome c and activation of caspases-9 and -3 (Lemasters et al, 1998; Duchen, 2000; 
Crompton, 2004). 
1.6.2.2 Glutamate excitoxicity and oxidative stress 
Mitochondrial dysfunction has been thought to be involved in the excitotoxic cascade 
triggered by glutamate. Glutamate excitotoxicity induced neuronal dysfunction and 
degeneration has been hypothesised to play a role in the pathogenesis of neurodegenerative 
diseases such as amyotrophic lateral sclerosis (ALS), AD and PD (Spalloni et al, 2013; Ong et 
al, 2013; Van Laar et al, 2015). Glutamate is a major excitatory neurotransmitter in the brain. 
It is released from vesicles in presynaptic terminals by a calcium dependent mechanism to 
produce an excitatory post-synaptic potential, which is involved in the activation of 
receptors for long term potentiation (Meldrum, 2000). Glutamate action is terminated by 
uptake systems located at the synapse and in the astrocytes surrounding the synapses. 
Glutamate can be converted to glutamine in astrocytes then released into the extracellular 
space. Glutamine is then picked up by neurons and converted back to glutamate, which is 
packed into synaptic vesicles by the vesicular glutamate transporters (Spalloni et al, 2013).  
Glutamate excitotoxicity means over activation of NMDA/AMPA receptors by excessive 
glutamate, allowing a large Ca2+ influx into cells and leading to intracellular Ca2+ 
accumulation (White & Reynold, 1996; Spalloni et al, 2013).  In part, the increased 
intracellular Ca2+ causes enhanced metabolic stress on mitochondria and results in 
mitochondrial membrane depolarization and opening of the mPTP, ROS production and 
caspase activation (White & Reynold, 1996). Studies of murine NCLs suggested excitotoxicity 
as part of the pathogenesis of NCLs (Griffin et al, 2002; Kovács et al, 2006; Kovács & Pearce, 
2008). There were no disease related glutamate concentration changes in CSF in ovine NCL, 
indicating glutamate/glutamine cycling is not a defect in all NCLs (Kay et al, 2009). Thus 
excitotoxicity is unlikely to be a common cause of neurodegeneration in all NCLs.  
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N-terminal domain and a mixed α/β terminal domain. The metal binding site lies on the 
interface of the two domains (Fig 1.2; Perry et al, 2010). The metal ion is stabilised by four 
metal ligands and a buried solvent (polar) molecule, forming the active site (Fig 1.2). Other 
residues arising from outside the active centre (Fig 1.2) facilitate the stability of the active 
centre and the resultant structure is important for the catalytic function of the enzyme 
(Yamakura et al, 1995; Whittaker & Whittaker, 1997).  
 
 
Figure 1.2 Three dimentional structure of human MnSOD. (A) The wild-type 
homotetrameric MnSOD structure 
(http://www.rcsb.org/pdb/explore.do?structureId=1LUV), with the four 
separate polypeptide chains coloured cyan, blue, green and yellow, and the 
active site manganese ions depicted as purple spheres. (B) The central active 
site of MnSOD is on the interface of the two domains of each subunit. The 
four metal binding ligands in the active site (His26, His74, His163, and 
Asp159) are shown to bind to manganses (Mn) and form a central active 
sphere in conjunction with a solvent molecule. A hydrogen-bonding network 
extends from the metal-bound sphere. Two outer-sphere residues, Gln143 
and Tyr34, are also linked to the active centre by the key hydrogen bond. A 
conserved water molecule then mediates the hydrogen bond between Tyr34 
and His30, and the latter also forms a hydrogen bond with Tyr166 from an 
adjacent subunit (Perry et al, 2010). 
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The catalysis of MnSOD takes place through a redox process in which the metal cycles 
between oxidised and reduced states: 
Mn3+ + O2- →Mn2+ + O2 
Mn2+ + O2- →Mn3+ + H2O2 
1.6.4.2 Inducible nitric oxide synthase (iNOS) 
Endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS) and iNOS are 
responsible for the conversion of L-arginine to L-citrulline and NO, in the presence of several 
co-factors including nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN) and tetrahydrobiopterin (BH4) (Mattila & 
Thomas, 2014). The catalytic activities of constitutively expressed eNOS and nNOS are 
calcium dependent and yield a low concentration of NO that serves as a signalling molecule 
and vasodilator (Griffith & Stuehr, 1995; Garthwaite & Boulton, 1995; Mattila & Thomas, 
2014). On the other hand, NO produced by iNOS in cells such as neutrophils and 
macrophages, has been postulated to play roles in activities against pathogens and 
suppression of proliferating cancer cells (Babior et al, 1973; MacMicking et al, 1997; Xu et al, 
2002). These activities of NO and the expression of iNOS appear to be mainly established in 
rodents but remain controversial in other species (Albina, 1995, Jungi et al, 1996; Vitek et al, 
2006; Gross et al, 2014).   
Activated microglial cells were thought to induce iNOS expression in vitro and in vivo in 
rodents (Dringen, 2005; Saha & Pahan, 2006). Activated iNOS was suggested to release a 
significant amount of NO that leads to neurodegeneration in diseases such as multiple 
sclerosis, AD and lysosomal disorders (Pannu & Singh, 2006).  
1.6.4.3 Haem oxygenase 1 (HO-1) 
Haem oxygenases are primarily responsible for degradation of Haem into equimolar 
amounts of labile iron, carbon monoxide and biliverdin (BV) (Tenhunen et al, 1968). Under 
physiological conditions, haem serves as a stable prosthetic group bound to Haemproteins. 
The free haem released from these proteins during oxidative stress has been proposed to 
cause further oxidative damage (Gozzelino et al, 2010). Two isozymes have been 
evolutionarily conserved (Tenhunen et al, 1968). HO-1 is the inducible form of haem 
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oxygenase and is thought to be regulated by oxidative stress (Kutty et al, 1994a; Choi & 
Alam, 1996). Cells that lack HO-1 expression show more susceptibility to oxidative stress 
(Poss et al, 1997; Yet et al, 2003; Bishop et al, 2004).  
The role of HO-1 in oxidative stress is not explicit. Free haem was thought to cause oxidation 
through the Fenton reaction, in which the ferrous ion (Fe2+) in free haem could be oxidised 
by H2O2 to form Fe3+, a •OH and a hydroxide ion (Fenton, 1894; Poss et al, 1997; Yet et al, 
2003; Bishop et al, 2004). Paradoxically, the resultant catalysis of free haem by HO-1 could 
also lead to oxidation. The accumulation of the free iron that is thought to underly the iron 
deposition theory of aging, AD, and PD, was also thought to contribute to the Fenton 
reaction (Schipper et al, 2009a). The ferritin and ferroportin iron sequestration pathways 
may obviate potential toxicity related to the intracellular accumulation of Haem-derived iron 
(Ryter et al, 2006; Zhang et al, 2014). 
HO-1 is also associated with anti-inflammation, but the mechanism is also not clear. The 
anti-inflammatory actions of HO-1 have been related to regulation of ectopic expression of 
NF-κB -dependent cytoprotective genes and inhibition of the apoptotic MAPK signalling 
pathway (Gozzelino et al, 2010). Anti-inflammatory cytokines such as IL-10 and TGF-β could 
stimulate expression of HO-1, whereas pro-inflammatory cytokines such as INF-γ repress 
expression of HO-1, suggesting HO-1 may be implicated in the anti-inflammatory actions 
elicited by anti-inflammatory cytokines (Kutty et al, 1994b; Ryter et al, 2006). 
The bile pigment (a soluble greenish pigment) produced by HOs (HO-1 and -2) catalysis, 
biliverdin (BV), can be converted by biliverdin reductase (BVR) to produce bilirubin (BR), a 
hydrophobic yellowish pigment that partitions to the lipid phase. BR is then excreted from 
cells and tissues and enters the blood by binding to albumin. It is removed from the serum 
exclusively by the liver, where it is metabolised to mono- and diglucuronides by hepatic 
glucuronyltransferases to become soluble and eventually passes from the liver through the 
bile to the faeces. In faeces, it is further degraded to urobilinogens by the reductive 
processes of intestinal microorganisms. The albumin-bound BR is thought to be an anti-
oxidant through its ability of scavenging peroxyl radicals in plasma and the extravascular 
space (Stocker et al, 1987). The other by-product, carbon monoxide, is suggested to act 
similarly to NO by modulating guanylate cyclase to increase intracellular concentrations of 
the second messenger (cGMP) (Verma et al, 1993; Fukuda et al, 1996). 
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1.6.5 Neuroinflammation in neurodegeneration 
The central nervous system (CNS) is considered to be immune-privileged, since the BBB and 
cerebrospinal fluid (CSF) form a barrier which restricts the entry of plasma proteins and 
immune cells to the brain. There is a lack of dendritic cells and lymphatic vessels in the brain 
(Perry, 1998). These features, along with perivascular macrophages, neuroglia and non-
neuronal cells (eg. pericytes), are responsible for structural support, maintenance of 
homeostasis, and immune surveillance of the CNS. Following damage, activation of microglia 
and astrocytes can cause breaches of the BBB and consequently an influx of peripheral 
macrophages and lymphocytes which exacerbate the inflammatory response. 
1.6.5.1     Glial activation 
Astrocytes form a symbiotic connection with neurons in conjunction with oligodendrocytes 
in the brain parenchyma and affect neuronal functions by releasing neurotrophic factors, 
guiding neuronal development, contributing to neuronal metabolism and regulating 
homeostasis. Astrocytic foot processes are in close apposition to the abluminal surface of 
the microvascular endothelium of the BBB thereby helping to support its structural and 
functional integrity (Dong & Benveniste, 2001). They typically exhibit a star-shaped 
morphology, with many processes extending from their soma. A number of functions have 
been attributed to astrocytes, including the biochemical support of neurons and other cell 
types, involvement in the repair of the brain (scar formation) following mechanical or 
inflammatory injury and support of endothelial cells forming the BBB. Astrocytes, are 
identified immunohistologically by the expression of the intermediate filament glial fibrillary 
acidic protein (GFAP), undergo proliferation and morphological change upon activation. 
Ablation of astrocytes in a forebrain stab injury in transgenic mice led to neurodegeneration, 
increased infiltration of blood-born inflammatory cells and phagocytic macrophages, and 
increased unguided outgrowth of nerve fibres (Bush et al, 1999). This study demonstrated 
clearly that astrocytosis is essential to maintaining the integrity of the BBB, and supportive of 
neuronal survival and neurite out-growth after CNS injury. However, astrocytosis has also 
been proposed to have a detrimental effect when chronically activated. Prolonged 
astrocytosis leads to aberrant expression of cytokines and chemokines that may be harmful 
to the neurons in neurodegenerative diseases (Dong & Benveniste, 2001).  
Microglia are resident brain macrophages, derived from myeloid cells which migrated to the 
CNS during embryogenesis (Kettenmann et al, 2011). They are regarded as sensors of 
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pathology and become activated when there is a change of the environment such as the 
presence of infectious agents and changes of neuronal activity (Perry et al, 2010; 
Kettenmann et al, 2011). Microglial activation is a common hallmark of neurodegeneration 
(Perry et al, 2010). Microglia are normally in a resting state and become activated upon CNS 
insult and migrate to the sites of the insult by following chemotactic gradients. Upon 
activation, microglia release inflammatory mediators aiming for the protection and 
restoration of CNS homeostasis. The activated microglia could be phagocytotic and able to 
clear tissue debris, damaged cells or invaded bacteria/virus (Kettenmann et al, 2011). Early 
studies have suggested microglial activation facilitated neuronal regeneration, delayed 
neuronal death and supported neurogenesis (Streit, 2002; Ziv et al, 2006). In contrast, 
microglial activation has also been proposed to contribute to the progression of 
neuroinflammation and neurodegeneration. Neurotoxic effects of microglial activation 
following acute insults have been reported (Krady et al, 2005; Purisai et al, 2007). Upon 
activation, microglia may release neurotoxic molecules such as pro-inflammatory cytokines 
and ROS that are involved in the neurodegenerative process (Gao & Hong, 2008; Perry et al, 
2010).  
The opposing roles of microglial activation have been attributed to the plasticity and the 
distribution of microglia. Microglia are capable of switching between phenotypes, which are 
associated with either regulatory or detrimental functions, activated by different molecular 
cues (Perry et al, 2010). Depending on the types of microglial phenotypes, progression of the 
disease and the interplay with other cells in the CNS, functions of microglial activation could 
be quite opposite, either protective or threatening (Perry et al, 2010; Cherry et al, 2014). 
Moreover, regional differences in microglial populations, their inflammatory responses and 
their interactions with other cells, such as astrocytes, may influence the final outcome of 
their activation (Gao & Hong, 2008). For instance, microglia isolated from the subventricular 
zone (SVZ) or the cerebellum of adult mice have different influences on the rate of 
neurogenesis (Walton et al, 2006).  
1.6.5.2      Neuroinflammation leads to the BBB breach  
The BBB provides a physiological barrier between the blood and the CNS to prevent blood-
borne pathogens and toxins entering the CNS. The BBB is located at cerebral blood vessels 
and the choroid plexus epithelium and is absent in the circumventricular organs (CVOs) 
(Weiss et al, 2008). CVOs are an integral part of neuroendocrine function in brain. They have 
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a rich vascular plexus with a specialised arrangement of blood vessels which lack BBB and 
allow diffusion of large molecules (Abbott et al, 2006; Weiss et al, 2008).  
The BBB barrier is formed by capillary endothelial cells, surrounded by basal lamina and 
astrocytic perivascular end-feet. It acts as a physical barrier as a result of the tight junction 
proteins between the endothelial cells adjacent to the cerebral blood vessels, and between 
the epithelial cells of the choroid plexus (Weiss et al, 2008; Abbott et al, 2006). These restrict 
most para-cellular molecular traffic. Some lipophilic molecules can diffuse through the lipid 
membrane and some molecules take a transcellular route across the BBB. Nutrients such as 
amino acids and glucose are actively transported by a variety of transporters on the 
endothelial membranes while some transporters are energy-dependent and act as efflux 
transporters. Other transport pathways include receptor-mediated transcytosis and 
adsorptive-mediated transcytosis (Abbott et al, 2006). In addition, neurovascular units 
comprised of microvascular endothelia, astrocytes, pericytes, neurons, and the basal lamina 
form a functional unit which regulates cerebral blood flow through homeostatic mechanisms 
and thus maintains the BBB integrity (Abbott et al, 2006; Muoio et al, 2014).  
It has been proposed that BBB disruption is an early consequence of neuroinflammation and 
multiple mechanisms have been hypothesised (González et al, 2014). The selectivity and 
permeability of the BBB is susceptible to damage by pro-inflammatory cytokines such as IL-
1β and TNF-α (Stanimirovic et al, 1997; Matsumoto et al, 2014). Glial activation leads to the 
release of pro-inflammatory cytokines which trigger down-regulation of tight junction 
proteins in the endothelial cells of the BBB and result in increased permeability of the BBB 
(Nagyoszi et al, 2010). Pro-inflammatory cytokines also up-regulate the expression of cell 
adhesion molecules (CAMs) on the endothelial cell surface. These interact with lymphocytic 
surface proteins such as lymphocyte function associated antigen 1 (LFA-1) on leukocytes and 
result in trans-migration of leukocytes into the brain (Weiss et al, 2008; González et al, 
2014). A subpopulation of monocytes (a type of leukocyte) were reported to enter the brain 
and transform into microglia after BBB damage (Mildner et al, 2007). It has been suggested 
that pericytes are sensitive to TNF-α (Matsumoto et al, 2014). These cells seemed to be 
stimulated by TNF-α to produce a unique profile of cytokines and chemokines, which have 
been suggested to signal recruitment of immune cells to enter the BBB, as well as promoting 
microglial activation and proliferation (Matsumoto et al, 2014). Another in vitro study 
supported the notion that pericytes, under the influence of pro-inflammatory cytokines, 
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could produce more pro-inflammatory cytokines that facilitate neutrophil trans-migration 
(Pieper et al, 2013). Activated pericytes in vitro show phagocytic ability and could express 
pro-inflammatory proteins (eg. iNOS) and produce ROS and RNS (Pieper et al, 2014). Matrix 
metalloproteinases (MMPs) were thought to be elevated during inflammation to cause 
degradation of tight junction proteins and result in BBB breachs (Lakhan et al, 2013). 
1.6.5.3      Other signalling molecules proposed to be involved in neuroinflammation 
The PI3K signalling pathway plays a fundamental role in signal transduction in mammalian 
cells (Engelman et al, 2006; Vanhaesebroeck et al, 2010). It mediates adaptive immunity, by 
regulating the development, activation and differentiation of both B- and T-cells and 
activation of autophagy, as well as mediating the innate immunity (Beer-Hammer et al, 
2010; Wang et al, 2011; So & Fruman, 2012). PI3K signalling is also involved in vesicle 
trafficking in cells and synaptic plasticity in mature neurons (Falasca & Maffucci, 2009; Knafo 
& Esteban, 2012). An alteration in PI3K signalling has been implicated in neurodegenerative 
diseases such as AD (O’Neill et al, 2012). Although the common PI3K signalling mechanism is 
known, the exact mechanism of PI3K signalling involved in neurodegeneration is not fully 
understood. 
Recent studies suggest that progranulin and metallothioneins could be implicated in NCL 
disease mechanisms in pathways such as neuroinflammation and metal dysregulation 
respectively (Smith et al, 2012; Kanninen et al, 2013; Petkau & Leavitt, 2014). However, it is 
not clear what roles these molecules play in the proposed mechanisms.  
1.6.6 The regulation of pro- and anti-inflammatory cytokines 
Neuroinflammation is one of the key features in the pathogenesis of neurodegenerative 
diseases. In NCLs, progressive activation of astroglia and microglia precedes neuronal loss 
suggesting a causative link, but whether glial activation triggers neurodegeneration or is a 
stress response remains unclear (Oswald et al, 2005). Bi-directional communication between 
glia and neurons via pleitropic and multifunctional cytokines may influence the fate of 
neurons. A previous study showed a generalised and chronic up-regulation in anti- and pro- 
inflammatory cytokine gene expressions in the CLN6 affected cortex, concurrent with the 
initiation of neurodegeneration throughout the disease progression, suggesting an 
uncontrolled inflammatory response (Barry, 2011). This indicates a counter-active 
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mechanism in which anti-inflammatory cytokines fail to suppress inflammation thereby 
implying a rather complex and intricate signal transduction network in the disease.   
Progressive and chronic elevation of anti- and pro- inflammatory cytokines in the ovine NCL 
brain links to the co-existence of trophic and toxic pathways (Barry, 2011). The common 
molecular mechanisms regulating these pathways include the transcriptional pathways of 
pro-inflammatory cytokines (NF-κB, JAK/STAT, and MAPK) as well as the inhibition of the 
pro-inflammatory pathway via inhibiting the transcription of pro-inflammatory cytokines (eg. 
SOCS3). 
1.6.6.1      NF-κB    
NF-κB (nuclear factor of kappa light polypeptide gene enhancer) is a eukaryotic transcription 
factor which was discovered in B lymphocytes in 1986 and named after its function in 
transcription of immunoglobulin kappa light chain (Sen & Baltimore, 1986). It was later 
found to activate expression of immune-related proteins such as cytokines and acute phase 
response proteins (Ghosh et al, 1998). The NF-κB family includes members of p65 (RelA), 
RelB, c-Rel, p50/p105 (NF-κB1), and p52/p100 (NF-κB2) in the presence of homo- or 
heterodimers, including p50-p50, p65-p65, p50-p65, c-Rel-c-Rel, p50-p65-IkB (Ghosh et al, 
1998). The family members contain a distinct feature, a Rel homology domain (RHD) which is 
responsible for dimerisation, interaction with inhibitors and binding of DNA (Fig 1.3). The 
RHD also contains a nuclear localisation signal (NLS) for import into the cell nucleus. RelB, c-
Rel and p65 contain a trans-activation domain (TD) therefore they have intrinsic 
transactivating potential which p50 and p52 homodimers do not have. Therefore, p50 and 
p52 have to form heterodimers with RelB, c-Rel or p65 to be transcriptionally active (Ghosh 
et al, 1998). Homodimers of p50 and p52 also appear to be repressive of gene transcription 
because they do not have TD domains (Ghosh et al, 1998; Zhong et al, 2002). The most 
common heterodimer of NF-κB found in cells is p65/p50, commonly referred as NF-κB 
(Ghosh et al, 1998). 
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Figure 1.3 Protein domains of the NF-κB family. The black bar indicates the Rel 
homology domain (RHD), TD represents the transactivation domain, GRR is 
the glycine-rich region and LZ the leucine zipper. The black arrows indicate 
where endoproteolytic sites on p100 and p105 which are processed into p52 
and p50 (Ghosh et al, 1998). 
 
NF-κB occurs in cells in a latent, inactive form which is bound by the inhibitor, IκB. Activation 
of NF-κB dimers is regulated by a canonical or a non-canonical pathway for members of the 
NF-κB family (Hayden & Ghosh, 2008). In the canonical pathway, a signal transduction 
pathway of inflammatory molecules such as TNF- α leads to phosphorylation of IκB kinase β 
(IKK β). The phosphorylated IκB dissociates from the NF-κB - IκB complex and is targeted for 
ubiquitination and degradation. Meanwhile, the NF-κB homo- or hetero-dimers translocates 
to the nucleus where they up-regulate specific genes containing a consensus sequence, 5’-
GGGRNYYYCC-3’ (R: purine, Y: pyrimidine, N: flexible) (Ghosh et al, 1995; 1998; Müller et al, 
1995; Hayden & Ghosh, 2008).  
1.6.6.2      JAKs 
Janus kinases (JAKs) are non- receptor tyrosine kinases and four family members have been 
found in mammals, JAK1, JAK2, JAK3 and TYK2. JAK1, 2 and TYK2 are ubiquitously expressed 
in cells whereas JAK3 was found to be expressed mainly in cells of the haematopoietic 
system (Ihle & Kerr, 1995; Yeh & Pellegrini, 1999; Heinrich et al, 2003). JAK kinases play a 
role in a variety of biological processes relating to haematopoiesis and the immune response 
(Haan et al, 2002). They are known to regulate cytokine signal transduction together with 
activation of transcription factors (STATs).  
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JAKs are approximately 1,100 amino acids long with molecular mass between 120kDa and 
140kDa. The generic structure of a JAK kinase consists of 7 JAK homology (JH) domains 
ranging from JH1 at the carboxyl terminus to JH7 at the amino terminus (Wilks et al, 1991; 
Fig 1.4). These domains are functionally defined as FERM domains (JH7 and JH6), SH2-like 
domains (JH5-JH3), a pseudokinase domain and a kinase domain. The amino terminal of the 
FERM domain binds to the membrane –proximal box1/2 region of cytokine receptors (Zhao 
et al, 1995; Chen et al, 1997; Kohlhuber et al, 1997; Richter et al, 1998; Cacalano et al, 1999). 
The remaining domain of FERM was thought to facilitate and stabilise JAKs binding to 
cytokine receptors (Haan et al, 2008). The Src-homology 2 (SH2) like domain (JH3-JH5) was 
postulated to provide structural support for the FERM domain (Radtke et al, 2005).  
 
Figure 1.4     Representative features of JAKs domains. 
 
The kinase domain mediates kinase activity via phosphorylation of tandem tyrosine residues 
in the activation loop. For instance, key tyrosine residues are Tyr1007 and Tyr1008 in JAK2; 
and Tyr 980 and Tyr 981 in Jak3 (Feng et al, 1997; Zhou et al, 1997). Phosphorylated tyrosine 
residues lead to enhanced catalytic activation and the expulsion of the activation loop from 
the active site to expose a docking site for inhibitors, such as suppressor of cytokine 
signalling protein 1 (SOCS1) (Rane & Reddy, 2000; Flowers et al, 2004; Lucet et al, 2006).   
The pseudokinase domain retains considerable homology to the tyrosine kinase domain but 
lacks the functional motifs of typical kinase activity (Haan et al, 2012). The high conservation 
of the dual domain structure from the fly to mammals suggests functional necessity (Haan et 
al, 2012; sequence BLAST). Deletion or mutations of the pseudokinase domain led to 
defective JAK activation and downstream signalling (Russell et al, 1995; Candotti et al, 1997; 
Saharinen et al, 2000). The exact mechanism of how pseudokinase regulates kinase activity 
is unknown but one possibility is that the pseudokinase domain inhibits the kinase domain 
by an intramolecular interaction. A conformational change upon ligand-binding dimerisation 
of receptors and JAK kinases disrupts this interaction (Haan et al, 2012).  
JH7 JH6 
JH
5 
JH4 JH3 JH2-Pseudo-Kinase 
Domain 
JH1-Kinase Domain NH2 COOH 
FERM SH2-like 
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1.6.6.3      STATs  
The signal transducers and activators of transcription (STATs) are well characterised JAK 
substrates. There are 7 genes in mammals responsible for encoding proteins STAT1, STAT2, 
STAT3, STAT4, STAT5A, STAT5B, and STAT6 that are between 750 and 850 amino acids long 
(Kisseleva et al, 2002).  
The general structure of a STAT protein consists of an amino terminal domain (NH2), a coiled 
coiled domain (CCD), the DNA binding domain (DBD), a linker domain, a SH2/tyrosine 
activation domain and a carboxy-terminal transcriptional activation domain (TAD) (Fig 1.6). It 
has been suggested that the TAD domain exhibits divergence which contributes to the STAT 
specificity (Kisseleva et al, 2002; Goenka et al, 2003). Other features, including post-
translational configuration, formation of dimers, and tissue-specific distribution, account for 
STATs specificity (Kisseleva et al, 2002; Delgoffe & Vignali, 2013). 
 
Figure 1.5 Representative features of STATs proteins. Domains depicted: an amino-
terminal domain (NH2), a coiled-coil domain (CCD), the DNA binding domain 
(DBD), a linker domain, an SH2 domain, and a transactivation domain (TAD). 
Post-translational modifications are indicated. Grey balloon: arginine 
methylation for modulation of interactions with epigenetic machinery. 
Orange balloon: a phosphotyrosine site for dimerization. Black balloon: a 
serine phosphorylation site for modulating gene target specificity and 
transcriptional activity. Blue bubble: a modification site for PIAS. Protein 
inhibitor of activated STATs proteins (PIAS) inhibits the activation and nuclear 
accumulation of STAT proteins (Delgoffe & Vignali, 2013). 
 
The amino terminal domain (NH2) has been shown to mediate STAT dimer binding by 
stabilising dimer formation (Xu et al, 1996; Vinkemeier et al, 1996). A crystalised structure of 
NH2 CCD DBD SH2 TAD NH2 COOH Linker 
M M 
PIAS 
modification 
site 
P
Y P 
 48 
a tyrosine phosphorylated STAT1 dimer bound to DNA by Chen et al (1998), revealed a 
model of the binding mechanism of a STAT dimer to DNA: A core DNA binding element 
consists of two monomers from each STAT and each monomer consists of the SH2 domain, 
the linker domain, the coiled-coil domain and the DNA binding domain. This core DNA 
binding element clamps a traversing DNA fragment (Fig 1.6).  
 
Figure 1.6  A crystal structure of the core human STAT1 and DNA complex (retrieved 
from Chen et al, 1998). 
The SH2 domain is highly conserved among the STATs and plays an essential role in STATs 
signalling. The domain contains a strictly conserved arginine residue, such as Arg-602 in 
STAT1, which recognises and docks to the phosphotyrosine on the receptor (Chen et al, 
1998).  
The surface of the coiled coil domain is mainly hydrophilic which enables interactions with 
other proteins such as co-activator proteins (Bhattacharya et al, 1996; Horvath et al, 1996; 
Zhang et al, 1999; Zhu et al, 1999). A small cluster of hydrophobic side chains associates with 
the binding of DNA (Chen et al, 1998). 
The DNA binding domain recognises a GAS (gamma-activated sequence) element, which is 
an 8 to 10 base pair inverted repeat DNA sequence of 5’-TTC(N2–4)GAA-3’ (Nx refers to the 
number of nucleotides in between the palindromic sequence, Ehret et al, 2001). Other 
binding sequences of STAT dimers similar to a GAS element include ISRE (interferon-
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stimulated response element) and GAS- like element or cis-inducible element (Aaronson & 
Horvath, 2002).  
1.6.6.4    JAK/STAT 
JAK- STATs comprise a signalling cascade involved in cytokine signal transduction. Four 
members of the JAK family (JAK1, 2, 3 and TYK2) and 7 members of the STAT family (STATS1, 
2, 3, 4, 5A, 5B and 6) have been discovered (Campbell, 2005). The suggested mechanisms of 
binding and activation of the JAKs in the receptor complex are largely theoretical (Haan et al, 
2012; Babon et al, 2014). Cytokines binding to their corresponding receptors trigger 
dimerisation of these receptors and recruitment of JAKs to juxtapose the cytosolic part of 
the receptors, in which JAKs phosphorylate STATs (Haan et al, 2012). 
Constitutive expression of JAKs and STATs in the CNS is lower than in other tissues 
(Campbell, 2005; Nicolas et al, 2013). JAKs and STATs (especially JAK1, 2 and STAT1, 3, 6) 
seem to be expressed actively during brain development and decline when the brain reaches 
maturation (De-Fraja et al, 1998). Studies also show a correlation between the JAK/STAT 
pathway and those of neurogenesis and astrogliogenesis, probably mediated by various 
cytokines and growth factors (Bauer, 2009; Gómez-Nicola et al, 2011). Expression of STATs 
appears to vary in cell types: STAT1 is highly expressed in neurons and moderately in glial 
cells while STAT4 is thought to be restricted to infiltrated T-lymphocytes and macrophages 
(Maier et al, 2002). Under pathological influences, the expression of STATs is dependent on 
the stimulation of different cytokines and cell types.  
1.6.6.5     MAPK 
Mitogen-activated protein kinases (MAPKs) are one of the central signalling hubs activated 
in response to changes in the extracellular milieu. The well characterised MAPKs are the 
extracellular signal-regulated kinases (ERK1/2), C-Jun NH2-terminal kinases (JNK-1/2/3), p38 
and ERK5 (Huang et al, 2009). These enzymes contain a conserved motif, TXY (T, threonine; 
Y, tyrosine; X, = glutamate in ERK, proline in JNK, or glycine in p38) in the activation loop of 
the kinases (Cuenda & Rousseau, 2007; Huang et al, 2009). MAPKs are fully activated by the 
dual phosphorylation of threonine and tyrosine in the conserved motif (Huang et al, 2009). 
MAPK kinase kinases (MKKKs) can be activated by physical and chemical stimuli to 
phosphorylate MAPK kinases (MKKs), which in turn phosphorylate MAP kinases (Cuenda & 
Rousseau, 2007; Huang et al, 2009). Activated MAPKs regulate key cellular events in the 
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cytoplasm by phosphorylation of membrane-associated and cytoplasmic proteins, including 
other kinases and cytoskeletal elements, as well as translocating to the nucleus to 
phosphorylate transcription factors for downstream gene expression (ter Haar et al, 2007; 
Huang et al, 2009). 
The p38 MAPK pathway is suggested to be activated by stress to regulate an immune 
response, cell survival and differentiation (Cuadrado & Nebreda, 2010). The first p38α MAPK 
was discovered as a 38kDa protein phosphorylated on tyrosine when cells were exposed to 
inflammatory stimuli and stress (Han et al, 1994; Rouse et al, 1994). Specific inhibition of the 
p38MAPK pathway led to down-regulation of pro-inflammatory cytokines (Hill et al, 2008). 
Subsequently, three isoforms were discovered to be expressed in a tissue-specific manner. 
They are p38β in brain, p38γ in skeletal muscle, and p38δ in endocrine glands. P38α is 
ubiquitously expressed at a high level in most cell types (Cuadrado & Nebreda, 2010). The 
p38s exhibit some functional redundancy (Sorrentino et al, 2008; Yamashita et al, 2008). 
The 3D structure of p38α MAPK contains a N- and C-terminal domain, an ATP binding site, a 
catalytic loop, a docking groove, and a substrate binding groove (ter Haar et al 2007). The 
docking groove is important for the binding of activators and substrates (Chang et al, 2002). 
Phosphorylation of the activation residues of p38α induces a conformational change and 
opens the substrate binding groove, in which the phosphorylation of the substrate takes 
place (ter Haar et al, 2007). 
The p38 MAPK pathway was thought to promote pro-inflammation. An anti-inflammatory 
cytokine, TGF-β, seems to associate with cell apoptosis through activation of the TRAF6-
TAK1 pathway (Sorrrentino et al, 2008; Yamashita et al, 2008). Upon TGF-β binding to its 
corresponding receptor, TRAF6 (TNF receptor associated factor 6) was recruited to the 
ligand –receptor complex and led to auto-ubiquitylation of TRAF6. The autoubiquitylated 
TRAF6 promoted modification of TAK1 (TGF-β associated kinase 1), a member of the 
mitogen-activated protein kinase kinase kinase family, resulting in its activation. TAK1 then 
activates the p38MAPK pathway (Sorrentino et al, 2008). Pro-inflammatory cytokines such as 
TNF-α and IL-1β have also been suggested to activate p38MAPK via activation of the TRAF6- 
TAK1 pathway (Wang et al, 2001; Shim et al, 2005). The activated p38 MAPK up-regulates 
cytokine production by directly phosphorylating their associated transcription factors such 
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as ATF2 and CREB. Also, the pathway directly or indirectly stabilises and increases the 
translation of pro-inflammatory cytokines (Schieven, 2005).  
1.6.6.6     SOCS 
Suppressor of cytokine signalling (SOCS) proteins are intracellular molecules that negatively 
regulate pro-inflammatory cytokine signalling via inhibition of JAK/STAT. They play roles in 
innate and adaptive immunity by regulation of macrophage and dendritic-cell activation, T-
cell development and differentiation (Yoshimura et al, 2007). SOCS proteins are generally 
present in low concentrations and expression increases rapidly upon cytokine activation 
(Alexander & Hilton, 2004). There are seven SOCS proteins (SOCS1-7). The inhibitory actions 
of SOCS proteins are facilitated by their structural features. The common features include a 
central SH2 domain, an amino-terminal domain of variable length and divergent sequence, 
and a carboxy-terminal 40-amino-acid peptide known as the SOCS box. The SOCS box is 
conserved in the SOCS family and interacts with components of proteosomal pathway so 
that the transducers bound by SOCS proteins can be targeted for degradation (Hilton et al, 
1998; Zhang et al, 1999; Yoshimura et al, 2007; Babon et al, 2008). SOCS1 and 3 can directly 
inhibit JAK tyrosine kinase via their kinase inhibitory region (KIR) near the amino-terminus as 
well as preventing signalling complex assembly (Yoshimura et al, 1995; Matsumoto et al, 
1997; Flowers et al, 2004; Waiboci et al, 2007; Dimitriou et al, 2008).  
1.7 Neurotrophic factors and the endosomal-lysosomal pathway 
Studies of chimeric animals produced by fusing normal and affected 16-32 cell embryos 
showed that there is intercellular correction in the CLN6 sheep despite the intracellular 
membrane location of the CLN6 protein. Chimeras showed normal-like or recovering 
physical growth and lack of cortical neurodegeneration despite up to 75% of the cells in the 
brain being genotypically affected (Barry 2011).  Glial activation was reduced or absent in 
these animals but neurogenesis was unusually active throughout the cortical grey and white 
matter. Therefore, given the correct environmental milieu disease-affected and newly 
generated cells are amenable to correction by normal cells in CLN6 NCL, resulting in an 
amelioration of disease pathology.   
It is reported that neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), 
fibroblast growth factor-2 (FGF-2), insulin-like growth factor-1 (IGF-1) and vascular 
endothelial growth factor (VEGF) are involved in the enhancement of adult neurogenesis, 
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either by direct effects on neuronal generation, or indirectly via the promotion of newly 
generated neuron survival (Palmer et al, 1995; Aberg et al, 2000; Lee et al, 2002; Jin et al, 
2002). 
Neurotrophic factors promote neuronal survival, stimulate axonal growth and play a key role 
in construction of the normal synaptic network during development (Yuen et al, 1996; 
Grimes et al, 1996).They help to maintain neural functions in adults, therefore any 
alterations in their local synthesis, transport or signalling could adversely affect neuronal 
survival and lead to neuronal death (Connor & Dragunow, 1998). Neurotrophins bind to their 
cell surface receptors and can be internalised and retrogradely transported in neurites 
(Miller & Kaplan, 2001; Bronfman et al, 2007). Neurotrophic factors binding to their 
corresponding receptors cause clathrin-coated vesicles to pinch from the membrane and 
move on to become “early endosomes”. From here, internalized receptors and ligands can 
be sorted to recycling endosomes and transported back to the plasma membrane for the re-
use of receptors and re-release (and potentially re-use) of ligands. Alternatively, the early 
endosomes mature as late endosomes and eventually fuse with lysosomes for degradation 
(Bronfman et al, 2007). Alterations in the endosomal-lysosomal pathway could result in 
altered processing and degradation of these factors. 
1.8 Research rationale 
Glial activation occurs prior to neurodegeneration, which follows in a regionally specific 
manner, suggesting that neuroinflammation plays a central role in the pathogenesis of ovine 
CLN6 (Oswald et al 2005; Kay et al, 2006). Inhibition of neuroinflammation by minocycline 
was not successful (Kay & Palmer, 2013). This validates an investigation into underlying 
mechanism of the neuroinflammatory pathway in ovine CLN6. The study of the molecular 
mechanisms underlying glial activation revealed the unbalanced signalling of pro- and anti-
inflammatory cytokines prior to neurodegeneration (Barry, 2011). However, it is not 
understood what could cause the abnormal inflammatory response. Therefore, the aim of 
this research is to further define the cytokine signalling pathways and if possible pinpoint the 
lesions in the neuroinflammatory pathway mediated by the uncontrolled cytokine response. 
If the lesions are found, more targeted drugs could be selected for therapeutic intervention 
of this devastating disease, and perhaps used in conjunction with gene therapies being 
developed for ovine CLN5 and CLN6.  
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A schema of the possible neuroinflammatory pathway summarised the selected signal 
transductions discussed previously and the elements potentially involved in 
neuroinflammation is shown in Figure 1.7 (Glass et al, 2010). The neuroinflammatory 
pathway comprises innate and adaptive immune responses. Briefly, the hypothesis is that 
the genetic defect caused by CLN6 mutations leads to glial activation, which produces pro- 
and anti- inflammatory cytokines via transcription regulation which in turn mediate the 
neuroinflammation (Raivich et al, 1999; Li & Verma, 2002; Kumar et al, 2003; Baker et al, 
2009; Brown & Neher, 2010; Minogue et al, 2012). Pro-inflammatory cytokines may then 
play a role in maintenance of this glial activation. The pro-inflammation overwhelms neurons 
resulting in neuronal injury and cell death. Meanwhile, an anti-inflammatory pathway is 
activated, aiming to repair tissue damage and support neuron survival. 
Activated glial cells may produce large amounts of reactive oxygen species and synthesise 
iNOS that produces nitric oxide, which forms peroxynitrite with superoxide that leads to 
oxidative stress thereby sustaining pro-oxidation and glial activation. Oxidative stress causes 
neuronal injury and cell death that also becomes a source of reactive oxygen species and 
causes more oxidative damage (Mander & Brown, 2005). An adaptive immune response is 
triggered by pro-inflammatory cytokines and leads to breaches in the BBB, allowing entry of 
the lymphocytic immune cells into the brain which could damage neurons when activated 
(Lim et al, 2007; Weiss et al, 2008; Saha et al, 2012; Groh et al, 2013). A loss of neurotrophic 
support for selective neuronal populations, such as reduced expression of neurotrophic 
factors and their receptors, may contribute to the pathology of neurodegenerative diseases 
(Henderson et al, 2000; Kopan et al, 2004; Blesch, 2006). Other possible signalling molecules, 
including PI3K, progranulin and metallothioneins will be investigated for their potential roles 
in the neuroinflammatory pathway (Kanninen et al, 2013; Gӧtzl et al, 2014).   
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et al 2005; Frugier et al, 2008). Clinically normal CLN6 heterozygous South Hampshire and 
CLN5 heterozygous Borderdale sheep are used as experimental controls. No sign of disease 
has ever been noted in heterozygous animals. 
 
 
Figure 2.1 The CLN6 PCR product of 251bp was cleaved by restriction enzyme in South 
Hampshires. Lane 1. Molecular marker, a size standard with 300, 200 and 100 
bp bands Lane 2. Control sheep (GG), yielding products of 117 and 67 bp after 
enzyme digestion. Lane 3 and 4. Carrier sheep (GA), three bands of 184, 117 
and 67 bp are visible. Lane 5. Affected sheep (AA) shows two bands of 184 
and 67 bp (Tammen et al, 2006). 
 
The affected animals and the age matched controls were sampled at critical timepoints 
determined by marked pathological features in the disease progression noted previously, 
and summarised in the simplified diagram below (Fig 2.2; Section 1.5.2; Jolly et al, 1982; 
1989, Mayhew et al, 1985, Oswald et al; 2005; Kay et al, 2006). Glial cells are activated as 
early as prenatally (Kay et al, 2006). Neurodegeneration, predicted by glial activation and 
reflected by changes in neuron populations, initiates at 6 months. Clinical signs are obvious 
by 9 months and are associated with visual impairment and behavioural changes.  Advanced 
disease reflects a severe neurological phenotype, concomitant with the complete loss of 
vision, which is a result of atrophy of the occipital cortex and loss of photoreceptors in the 
retina by 18 months. The brain is severely atrophied and animals reach maximum life 
expectancy at 24 months.      
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(260/280nm) of RNA were measured by a spectrophotometer (NanoDrop Technologies Inc., 
Wilmington, DE, USA). RNA concentrations were determined by the optical density (OD)260 
multiplied by the RNA factor (40): 
40 x OD260 of the sample = concentration of RNA (μg/ml) 
RNA integrity was checked by separating 4µl of total RNA on 1.5% agarose gels in TBE 
(Appendix A.4) with RedSafe (iNtRON Biotechnology, Korea) 40min, 80V.  An image was 
captured using a GelDoc XR (Bio-Rad, USA) imaging system. Intact RNA was indicated by two 
crisp bands of ribosomal RNA species 28S and 18S (Fig 2.3).  
 
Figure 2.3 A representative image of the RNA integrity of a brain sample. 
 
Single stranded cDNA was synthesised from 450ng of total RNA in two 20µl reactions using 
Superscript III reverse transcriptase (Invitrogen, USA) as per instructions. RNA was diluted to 
a total volume of 13µl with RNase free water, 1µl of 10mM dNTPs (Invitrogen) and 2µl of 
50µM random hexamers (Invitrogen) and incubated, 65°C, 5min after which samples were 
submerged in ice for 1min. A first strand synthesis master mix consisting of 1X First Strand 
buffer, 200U Superscript III polymerase and 40U RNaseOut recombinant ribonuclease 
Inhibitor (Invitrogen) was prepared and a 7µl aliquot added to each sample. All PCR 
reactions were carried out on a Mastercycler Gradient PCR machine (Eppendorf, Hamburg, 
Germany). An incubation program was used: 1 cycle at 25°C for 5mins, then at 50°C for 
50mins and at 70°C for 15mins. Following cDNA synthesis, replicate samples were pooled 
and 5µl aliquots frozen at -20°C. The remaining RNA samples were stored at -80°C. 
28S 
18S 
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supplied buffer to melt the agarose. The solubilised DNA was washed and eluted in 30µl of 
eluent (2.5mM Tris-Cl, pH 8.5) on miniprep columns, supplied in the AxyPrep DNA gel 
extraction kit. Three µl of each purified DNA was run on 1.5% agarose gels for estimation of 
the concentrations and some was sent for sequencing (as indicated in 2.3.4), using the 
external primer pair to confirm the correct PCR product. 
Insertions of 50ng of product into the sequencing vector pGEMT-easy (Promega Corporation, 
Madison, WI, USA) were completed by the incubation with ligation reaction mixture 
overnight at 4°C. Each 10µl ligation reaction mixture contained a 1:1 ratio of pGEMT-easy 
vector and insert, 2X rapid ligation buffer and 3U of T4 DNA ligase. 
A microfuge tube containing 2µl of ligation mix and 50µl of competent cells (Escherichia coli 
DH5α, Invitrogen) were placed on ice for 20min, followed by heat shock at 42°C, 2min, and 
then immediately put on ice for a further 2 min. Super optimal broth medium (SOC), 950µl, 
was added and the transformation mix incubated in a shaking incubator at 850rpm, 90min, 
37°C. Meanwhile, selective lysogeny broth (LB) agar plates were pre-warmed at 37°C for 
later usage. These selective LB agar plates contained of 100µg/ml ampicillin (Duchefa 
Biochemie B.V, Haarlam, Netherlands), 0.5mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(Sigma, USA) and 50mg/ml X-Gal (Quantum Scientific, Milton, Qld, Australia). 
A 100µl and a 200µl transformation of competent cells with the ligated plasmid were plated 
onto separate LB agar plates and incubated at 37°C overnight. Following incubation, a single 
white colony from one of the LB + ampicillin plates was used to inoculate a 20µl PCR mix to 
check for the insertion of the intended sequence. A standard PCR was performed. Insertion 
was indicated by the appearance of a single band of the expected size. A 1ml starter culture 
(LB broth, 100µg/ml ampicillin) was inoculated with the selected colony and was grown for 
4h, 37°C. This starter culture was then added to 10ml of LB broth containing 50µg/ml 
ampicillin and grown up overnight at 37°C in a shaking incubator at 250rpm. Several 500µl 
aliquots of the culture was mixed in glycerol and stored in cryotubes at -80 °C.  
Isolation of plasmid DNA was completed by the AxyPrep plasmid miniprep kit (Axygen). A 
1.5ml sample of the remaining culture was centrifuged to pellet cells, which were 
resuspended in the supplied buffer, lysed, and centrifuged for 10min, 12,000rpm, to pellet 
the bacterial DNA, protein, and cell debris. The resultant supernatant was transferred to a 
spin column, washed and centrifuged to adsorb plasmid DNA to the silica-gel membrane. 
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the tissue specificity of the metal metabolism (eg, the elevated copper concentration of 
storage bodies in liver) (Palmer, 1987). The presence of metals did not facilitate lipid 
peroxidation since there was no evidence of lipid peroxidation (Palmer, 1987; Palmer et al, 
1988; Jolly et al, 2002).  
The abnormal accumulation of the subunit c was proposed to arise from a mutant expressed 
pseudogene or the trimethylation on lysine 43 (Palmer et al, 1990; Medd et al, 1993). These 
ideas were discounted when the genes and their levels of expression were found to be 
normal in the affected sheep and the trimethylated lysine 43 a normal post-translational 
modification of all subunit c (Medd et al, 1993; Chen et al, 2004; Walpole et al, 2015). The 
protein sequence analysis of the subunit c revealed that the accumulated subunit c had been 
processed into the inner mitochondrial membrane prior to accumulation, indicated by the 
cleavage of the mitochondrial import sequence (Palmer et al, 1992, Palmer, 2015).  
Subsequently, the subunit c of the mitochondrial ATP synthase was confirmed as the major 
protein stored in other animals and human NCLs for CLN2, CLN3, CLN5, CLN6, CLN7 and 
CLN8 (Animal models: Fearnley et al, 1990; Martinus et al, 1991; Jolly et al, 1994; Pardos et 
al, 1994; Palmer et al, 1997; Url et al, 2001; Cook et al, 2002; Katz et al, 2005; Melville et al, 
2005; Frugier et al, 2008; Human NCLs: Palmer et al, 1989a, 1989b, 1992; Hall et al, 1991; 
Kominami et al, 1992; Kida et al, 1993; Tyynelä et al, 1997; Herva et al, 2000; Palmer, 2015). 
These show that the storage of the subunit c is a norm in most forms of NCLs and suggest 
that a common pathological pathway, where different NCLs proteins play a part, underlies 
the pathological mechanisms of NCLs (Palmer, 2015). In the CLN1 and CLN10 forms, the main 
storage materials are the sphingolipid activator proteins (SAPs) A and D , which are small 
heat-stable glycoproteins required for the hydrolysis of sphingolipids in lysosomes (Mehl & 
Jatzkewitz, 1964; O’Brien & Kishimoto, 1991;Tyynelä et al, 1993; Siintola et al, 2006).  
As mentioned earlier, the burden of the storage bodies is not a direct cause of neuronal 
death (1.3.3). Moreover, the accumulation of the storage bodies occurs in nearly all cells of 
NCL patients, suggesting the accumulation is not damaging and is a separate consequence of 
the genetic lesion (Palmer et al, 2002; 2015). 
In spite of mounting evidence against the pro-oxidation hypothesis, pro-oxidation is still 
widely accepted as one of the driving mechanisms for NCLs. The underlying rationale is 
derived from the proposed oxidative stress that underlies the lipofuscin accumulation in 
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The H2O2 in turn may be fully reduced to water by catalases, glutathione peroxidases, and 
peroxiredoxins or partially reduced to hydroxyl radicals in the presence of chelatable iron as 
well as O2- (Halliwell, 1978).  
The radical character observed for O2-  has been over-emphasised and it is known not to be a 
super radical chemical (Sawyer & Valentine, 1981). It is believed the derived products such 
as HO2 and H2O2 are more reactive than O2- (Bielski et al, 1983; Forman & Thomas, 1986). O2-  
most frequently acts as a reducing agent and thus is unlikely to cause cellular damage by 
oxidative attack (Ross & Ross, 1977). HO2 is thought to initiate a lipid peroxidation chain 
reaction whereas H2O2 reacts with nitric oxide (NO) to produce peroxynitrite (ONOO-) 
(Bielski et al, 1983; Halliwell & Chirico, 1993; Moncada & Erusalimsky, 2002) but there is lack 
of in vivo evidence to support the notion (Section 3.1.1). In addition, the hydroxyl radical 
formation can be prevented by just small amounts of catalases or superoxide dismutases 
(Halliwell, 1978), indicating efficient removal of O2- by these enzymes and these enzymes can 
be tools for testing physiological processes for the involvement of O2-.  
Superoxide dismutases (SODs) efficiently eliminate O2-, and form a synergistic relationship 
with catalases and peroxidases for a defensive mechanism against O2- and O2- derivatives. 
O2- inactivates catalases and Haem-containing peroxidases by converting these enzymes to 
the poorly active form by oxidation of iron in Haem. SODs protect catalases and peroxidases 
against this inactivation. At the same time, H2O2 inactivates superoxide dismutases and 
catalases or peroxidases prevent this (Fridovich, 1983). 
MnSOD (Manganeses superoxide dismutase) resides in the lumen of the mitochondrial 
matrix and functions to convert O2- to H2O2, which is then converted to water by catalases 
and glutathione peroxidases (Sayre et al, 1999). SOD1 (Cu-Zn SOD), and SOD3 (extracellular 
SOD; ECSOD; incorporating either copper or zinc) are a family of enzymes that catalyse the 
dismutation of O2-, which was proposed to be produced by phagocytosing neurophils as part 
of the bactericidal process (Babior et al, 1973). SODs were subsequently proposed to be 
protective of the neutrophil-generated superoxide (Salin & McCord, 1975). SOD1 encoded 
Cu-Zn SOD is primarily located in the cytoplasm of neurons and mutations of SOD1 cause 
amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disease associated with the 
relative selectivity of motor neuron cell death (Haidet-Phillips & Maragakis, 2015). The 
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overlapping roles and the abundance of the SODs in brain suggest an active defensive 
system against ROS. 
In a preliminary CLN6 study, MnSOD expression was reported to be significantly increased in 
CLN6 affected human fibroblasts and in the brains of CLN6 affected sheep (Heine et al, 
2003). Elevated MnSOD were also reported in PPT1-knockout mice neurospheres from a 
murine model of INCL (Kim et al, 2006b). Increased MnSOD expression was suggested to be 
a response to oxidative stress or to activation of glial cytokine production (Heine et al, 2003; 
Kim et al, 2006b). 
The haem oxygenases (HOs) are claimed to be sensors of cellular oxidative stress (Schipper 
et al, 2009a; b). These enzymes are located in the endoplasmic reticulum (ER) and degrade 
haem to carbon monoxide (CO), free ferrous ions (Fe2+) and biliverdin, which is further 
reduced by biliverdin reductase A (BVA) to form bilirubin (BR, bile pigment), in the presence 
of oxygen and NADPH cytochrome P-450 reductase. Two haem oxygenases, HO-1 and 2, 
have been described to be primarily involved in haem catabolism and erythrocyte turnover 
in the spleen, liver and bone marrow (Ryter et al, 2006). Neurotoxicity caused by HO-1 over-
expression has been associated with hyperbilirubinemia (also known as kernicterus in the 
brain), iron deposition, oxidative stress and mitochondrial injury (Qato & Maines, 1985; Beal 
et al, 1996; Schipper et al, 1998; Sayre et al, 2001). The accumulation of metals in cells is 
thought to make cells more vulnerable to the ROS and result in oxidative stress. This has 
been suggested to be part of the pathogenesis of AD, PD and NCL (Smith et al, 2009b; 
Schipper et al, 2009a; Van den Berge et al, 2012; Grubman et al, 2014). The pro-oxidant 
property of HO-1 is theoretically sound as the free ferrous ion (Fe2+) is a primary reactant in 
the Fenton reaction, where it reacts with hydrogen peroxide to form a reactive hydroxyl 
radical, a ferric ion and a proton (Fenton, 1894). The same theory has been applied to most 
studies that describe transitional metal-provoked oxidative stress. Nevertheless, there is a 
lack of evidence that it occurs in vivo (Section 3.1.1.)  
The anti-oxidative role of HO-1 has been suggested to be associated with bilirubin (Stocker 
et al, 1987; Doré et al, 1999). Gene knock-out studies of HO-1 showed cells became more 
susceptible to oxidative stress (Poss et al, 1997; Bishop et al, 2004). However, the anti-
oxidative role of bilirubin only took place when bilirubin bound to albumin (Stocker et al, 
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Table 3.1 Primer sequence information and reaction conditions for qPCR of oxidative 
stress markers 
Gene  GenBank accession 
number 
TA* Primer sequence (5’-3’) Product 
size 
(bp) 
Ovine iNOS 
 
 
AF223942.1 
 
57 ˚C External 
F- CCC CGT GTT CCA CCA GGA AAT GC 
R- TGG TCG ATG TCG TGA GCA AAA 
GCA 
510 
Internal  
F- GGA GGC CCC AGA GAA GAG AGA TT 
R- ACC TTG GGG TTG AAG GCA CAG C 
190 
Ovine MnSOD 
 
 
GQ221055.1 55 ˚C  External 
F- ACG GTG GGG GCC ATA TCA ATC AC 
R- AGC CAC GCT CAG AAA CAC TAC AAC 
509 
 
Internal 
F- TTC CGG TTG GGG TTG GCT TGG 
R- TGC AAG CTG TGT ATC GTG CAG T 
230 
Bovine HMOX1 NM_001014912.1 57 ˚C 
 
External 
F- GGC TTC CTT CCC TTG AGC TT 
R- TCA GCA ATC AAG GCC ACA GT 
498 
Internal 
F- AGC CTG AGA CAT CTC CAC CA 
R- AAG GGA GAC CTC AGA CCC AA 
186 
* Annealing temperature 
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Figure 3.1 Immunostaining for COX IV in the major nuclei of the sheep coronal section 
through the medulla and cerebellum.  F- flocculus, P- paraflocculus, VS- 
vermis superficial folia, VM – vermis mid folia, VD – vermis deep folia, IC – 
interposed cerebellar nucleus, MC - medial cerebellar nucleus, LC – lateral 
cerebellar nucleus, LV- lateral vestibular nucleus, MV – medial vestibular 
nucleus, SV – spinal vestibular nucleus, DC – dorsal cochlear nucleus, ST - 
spinal trigeminal nucleus, Gi –gigantocellular reticular nucleus, FN – facial 
nucleus,  R – raphe nucleus, RF – reticular formation, the major nuclei were 
identified according to the sources of Stockx et al, 2007, and  
https://www.msu.edu/~brains/brains/sheep/index.html. 
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3.3.1.1 Cerebellum 
There was no difference in immunoreactivities of MnSOD and COX IV between the affected 
and control cerebella (Fig 3.2). Immunostaining for MnSOD appeared to be more prominent 
in the cerebellum than the immunostaining for COX IV but a similar cellular staining pattern 
in cells was observed for MnSOD and COX IV. Moderate immunostaining for MnSOD and 
COX IV was found in some neurons in the molecular and granular layers. The Purkinje cells 
showed strong cytoplasmic immunoreactivity. 
 
 
Figure 3.2 MnSOD and COX IV immunostaining of control and CLN6 affected cerebellar 
cortex, normal (A, C) and CLN6 affected (B, D). Scale bar represents 100µm. 
 
3.3.1.2 Brain stem nuclei 
Neurons in the medulla and brainstem were immuno-positive for both MnSOD and COX IV, 
with no immunoreactive variation between nuclei or genotypes (Fig 3.3). Intense MnSOD 
and COX VI immunopositivity was localised adjacent to the cell nucleus, and was more 
diffusive towards the cell periphery and dendritic processes. The burden of storage bodies in 
Molecular layer 
Granular layer 
 83 
some affected cells resulted in ballooned cell bodies with associated punctate peripheral 
staining, although this was not a prominent feature in the affected vestibular neurons or 
other large neurons in the brainstem, such as the Raphe nuclei. (Fig 3.3 E, F, G, H). 
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Figure 3.3 Comparative MnSOD (A, B, E, F) and COX IV (C, D, G, H) immunostaining of 
large neurons in vestibular and Raphe nuclei in control and CLN6 affected 
sheep. The immunostaining intensity did not vary between control and 
affected animals. Storage bodies altered the peripheral staining of some 
affected cells, such that they exhibited a punctate appearance as indicated by 
red arrow-heads. Higher magnifications (the boxed neurons) show specific 
immunostaining of the respective antibodies. Scale bar represents 500µm. 
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3.3.1.3      Cerebral cortex 
In contrast to a lack of change of immunoreactivity of MnSOD in cerebella and brainstem 
between the controls and the affected, the immunoreactivity for MnSOD appeared to 
change with age in the affected cerebral cortices, as a darker band of staining was observed 
at 18 and 24 months (Fig 3.4). Although not shown, the macroscopic COX IV staining shared 
a similar trend and was similarly distributed (Fig 3.5).  
No immunoreactivity for either MnSOD or COX IV was observed in cells with glial 
morphology. Not all types of neurons were immunoreactive to MnSOD and COX IV. Positive 
staining was found in the medium to large size cells with the morphology of pyramidal 
neurons (Fig 3.5 A; B; Fig 3.6; 3.7). Some were found that morphologically resembled spindle 
neurons (Fig 3.5 A; B; Fig 3.6; 3.7). The definition for cortical layers was based on the 
distribution of the pyramidal neurons (Fig 3.5 A; B). MnSOD and COX IV immuno-reactive 
cells were primarily located throughout layers II to VI and showed heterogeneous expression 
between the cell types in controls (Fig 3.5 A; B; Fig 3.6; 3.7). It is important to note that these 
MnSOD and COX IV immunepositive cells were distributed sparsely and unevenly across the 
cortical layers II to VI in the controls (Fig 3.5 A; B). They appeared to become densely packed 
at the age of 18 and 24 months in the affected cortices when cortical thinning was evident, 
leading to an appearance of an increased number of immunoreactive cells (Fig 3.5 A; B). This 
reflected in the darker band seen in Fig 3.4. However, the intensity of immunoreactivity in 
the cells did not differ between the affected and control brains (Fig 3.6; 3.7), indicating the 
abundance of MnSOD and COX IV did not change in these cells. 
To confirm if all the immunoreactive cells for MnSOD and COX IV were preserved in the 
affected brains, these cells were counted and normalised to the number of immunoreactive 
cells in the controls. In this way, the shrinkage of the surface area in the affected animals 
was corrected for and the change in MnSOD and COX IV immunoreactive cells could be 
compared. The cell counts showed number of cells stained for MnSOD decreased 
significantly at 18 months, and more dramatically at 24 months, as did those 
immunoreactive to COX IV (Table 3.2). This means there was a disease-correlated reduction 
of MnSOD and COX IV immunoreactive cells. Since COX IV is a known mitochondrial marker 
and MnSOD is localised to mitochondria, the mitochondrial number were reduced in the 
affected cortices. 
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Table 3.2 Estimation of the reduction in MnSOD and COX IV immunoreactive cells in 
the CLN6 affected sheep brain at 18 and 24 months. Quantitative cell counts 
are presented as % of cell in comparison to the controls.  
Genes MnSOD COX IV 
Age/Brain Regions 18m 24m  18m 24m 
Frontal cortex 65 31 66 27 
Parietal cortex 60 23 54 26 
Occipital cortex 56 21 52 25 
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Figure 3.4 Immunoreactivity of MnSOD in sagittal sections from the affected animals 
at 2, 6, 12, 18 and 24 months of age, showing little variation in MnSOD 
immunoreativity with the progression of disease from 2 to 18 months. 
Sections at 24 months of age appear to have a slight increased staining in the 
parietal and occipital cortex, probably arising from higher background 
staining. Subcortical nuclei stained for MnSOD remained consistent between 
genotypes and ages. Boxed areas are presented at a higher magnification in 
Figure 3.5.
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Figure 3.6 Neuronal staining of MnSOD in cortical layer V at 18 months. Cells 
immunoreactive to MnSOD had the morphology of pyramidal neurons 
(indicated by the yellow arrowheads). Cell bodies were slightly enlarged in 
affected animals. Expression was heterogeneous between cells.  Scale bar 
represents 100 µm. 
 
Figure 3.7 Neuronal staining of COX IV in cortical layer V at 24 months. Similarly to the 
cells immunoreactive to MnSOD, cells stained for COX IV had pyramidal 
morphology (indicated by the yellow arrowhead). Expression was 
heterogeneous within individual cells and between cells. The large pyramidal 
neurons like cells, which were sparsely distributed in the normal cortical layer, 
were compressed at 18 months (Fig 3.5; 3.6) and more so in the affected 
cortices at 24 months. Scale bar represents 100 µm. 
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Figure 3.8 MnSOD, iNOS and HO-1 mRNA expression in the cortex of CLN6 
affected and control animals at 2, 6, 9, 18 and 24 months of age 
(n=4). *, significant difference (P < 0.05; paired t-test); **, highly 
significant difference (P < 0.01; paired t-test) compared to the value 
for control animals of the same age. Values depict the mean ± SEM for 
frontal, parietal and occipital brain regions for animals at each time 
point. 
 
Table 3.3 Fold change of SOD2 (MnSOD) 
Gene of Interest Age (months) Fold change in 
comparison to age-
matched controls 
Statistical 
significance*  
SOD2 2-9 - - 
18 4 ** 
24 3 * 
* -, not significantly different; *, <0.05; **, <0.01 
 
 
** 
* 
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and disease-related. The distribution of MnSOD and COX IV expression did not change in the 
cerebella and brain stem in the affected animals whereas they changed dramatically in the 
cerebral cortices. An appearance of slightly darker immunostaining for MnSOD was 
highlighted the affected cerebral cortices at 18 months and more so at 24 months at a 
macroscopic observation, but it was not seen in the earlier ages (Fig 3.4). This impression 
was contributed to the densely packed immunoreactive cells because of the compression of 
brain layers in neurodegenerative process (Fig 3.5 A, B). Cell counts of the immunoreactive 
cells revealed a disease-associated reduction of these cells the most reduced in the parietal 
and occipital cortex and less in the frontal cortex at 18 months (Table 3.2), in line with the 
regionality pattern of degeneration in a previous study (Oswald et al, 2005).  
The morphology of the immunoreactive cells of MnSOD and COX IV also coincides with the 
previous observation of which neurons remained at end-stage of disease, showing a 
selective degeneration of cell types in the disease progression. Nissl staining in the cerebral 
cortex of CLN6 affected sheep revealed pyramidal cells remained in layer V whereas 
pyramidal cells were largely missing from layer III in terminal disease at 24 months (Oswald, 
2004; Oswald et al, 2008). In humans, small cerebral neurons depleted earlier and faster 
than the larger neurons, such as the pyramidal neurons (Anderson et al, 2013). The 
immunoreactive cells were mainly medium to large cells with pyramidal neuronal 
morphology as well as some spindle-like cells in layer II to IV of neocortex in the controls (Fig 
3.5; 3.6; 3.7). Mainly pyramidal neuron like cells remained in the affected cortices at 24 
months (Fig 3.5). This means that the selective neurodegeneration in these immunoreactive 
cells is not dependent on the presence of mitochondria. 
Oxidative stress is hypothesised to be caused by metabolic stress resulting from mutated 
NCL genes and more storage bodies accumulating in cells, and that further increases the 
oxidative stress (Seefer & Pearce, 2006). This would mean that oxidative stress is a global 
insult and presumably all cells would be affected equally. In contrast to this hypothesis, the 
immunoreactive cells of MnSOD and COX IV did not degenerate equally but rather regionally 
only in the cortex, and not in the other brain regions.  
In addition, the intensity and pattern of the immunostaining for MnSOD and the 
mitochondrial marker (COX IV) in cells in the affected animals was similar to that in the 
controls, indicating no change in MnSOD abundance, nor any signs of abnormal 
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immunosuppression, cytotoxicity and inefficiency of iNOS expression are undesirable in the 
CNS (Albina, 1995).  
mRNA expression of iNOS was not found in the ovine brain in the present study, highlighting 
a species-dependent expression of iNOS. The iNOS-centred mechanism of inflammation and 
pro-oxidation should be discarded from the neuroinflammatory cascade in ovine and human 
NCL. The evidence emphasises variant inflammatory responses across species and that large 
animal models are more suitable than rodent models for the study of inflammation. 
The haem oxygenase-1 (HO-1; HMOX-1) is expressed at low quantities in the CLN6 affected 
brain. HO-1 may not even play an important role in the CNS. The primary role of HO-1 has 
been suggested to be involved in haem catabolism and erythrocyte turnover (Ryter et al, 
2006). High HO activity is found in tissues that degrade senescent red blood cells. The roles 
of HO are clearly explained in these cells: HO is present in the bone marrow to inhibit cellular 
differentiation by lowering the intracellular concentration of haem, which is a differentiation 
factor for haematopoietic stem cells. HO activity is increased significantly in response to 
increased circulating haemoglobin in the liver parenchyma, kidney and macrophages 
(Tenhumen et al, 1970; Pimstone et al, 1971a; b; Abraham et al, 1989; 1991). In traumatised 
brain, the induction of HO-1 in glial cells was thought to be a scavenging response to the 
metabolic by-products originating from lysed red blood cells (Fukuda et al, 1996; Matz et al, 
1996).  
Mitochondria are enriched with haemproteins that are potential substrates for HOs. 
However, a haem-degrading mitochondrial system, that has a higher catalytic activity than 
the activity of HOs derived from the microsomal fraction, has been suggested (Kutty & 
Maines, 1987). The haem-degrading mitochondrial system would be more useful for the 
tight control in turnover of the mitochondrial haemoproteins (Kutty & Maines, 1987). All the 
cases indicate the role of HOs is probably mainly in degradation of haem of haemoglobin and 
HO-1 is not likely induced otherwise. Although in vitro studies found induction of HO-1 in 
response to anti-oxidant treatment, pro-inflammatory stimuli, hormones, and growth factors 
(Kutty et al, 1994b; Ryter, 2006; Gozzelino et al, 2010), they have not been able to 
demonstrate a common mechanism. For the oxidative stress studies in the brain, HO-1 
expression was assumed to lead to the deposition of iron and subsequently induce the 
Fenton reaction-provoked oxidative stress (Schipper et al, 2009b). The storage bodies of 
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normal lymphocyte development, Shinkai et al, 1992), showed amelioration of the functional 
and clinical phenotypes and improved longevity (Groh et al, 2013).  
Other mechanisms of BBB disruption have been proposed including the modulation of tight 
junction proteins by pro-inflammatory cytokines which increases the BBB permeability, and 
activated metalloproteinases (MMPs) directly contributing to an alteration of the basal 
lamina (Weiss et al, 2008).  
Recent studies in INCL and JNCL mouse models have suggested an alteration of the 
permeability of the BBB and the infiltration of the active T cells, suggesting the adaptive 
immune response is involved, along with innate glial activation of the CNS (Lim et al, 2007; 
Saha et al, 2011). Breaches in the BBB allow the entry of the immune cells and their 
activation may damage neurons. Possible BBB disruptions can be investigated by using sheep 
specific antibodies for IgG and lymphocyte subsets expressing CD4 (T helper cells) and CD8 (T 
cytotoxic cells). These markers were used in previous studies of other NCLs (Lim et al, 2007; 
Groh et al, 2013). 
4.4 Materials and methods 
4.4.1 Animals 
Details are described in Chapter 2. Tissue from sheep aged 2 months were added to the 
mRNA study of cytokines. The same animals were used for quantitative PCR of cytokines in 
the previous study. 
4.4.2  RNA isolation and cDNA synthesis 
Methods of RNA isolation and single-stranded complementary DNA (cDNA) synthesis are 
described in detail in Chapter 2. 
4.4.3 Primer design and plasmid generation 
The method is described in Chapter 2. 
Primer pairs were designed to target the sequences shared between the transcript variants 
of a gene. Purified products generated by primer pairs were sequenced to ensure that the 
correct products were acquired and sequences of the ovine genes of interest were 
 109 
constantly updated particularly if the primer designs were based on the bovine sequences. 
Products of these primers were sequenced and aligned with the updated ovine sequence to 
confirm the correct targets.  
Table 4.1  Primer sequence information and reaction conditions for qPCR of 
neuroinflammatory markers 
Genes  Sequence reference 
in GenBank 
TA* Primers Expected 
product 
size (bp) 
Ovine 
JAK2 
XM_004004357.1 
(transcript variant 1) 
XM_004004358.1 
(transcript variant 2) 
55 ˚C External 
F- TGCCGGTATGACCCTCTACA 
R- ATGGGACTTTCACCAGGCTC 
458 
57 ˚C Internal  
F- GGTGGCTGTGAAAAAGCTCC 
R- GCCAGCACTGTAACAGACTC 
130 
Ovine 
STAT1 
NM_001166203.1 55 ˚C External 
F- CAATGCTTGCCTGGATCAGC 
R- CTCCCGTTGGTGGACTCTTC 
441 
57 ˚C Internal 
F- CACTGTAGTGGCGGAGAGTC 
R- GTTGAAGGTGCGGTCCCATA 
133 
Ovine 
STAT3 
JF267352.1 57 ˚C External 
F- CTTCTCCTTCTGGGTCTGGC 
R-TCGGCAGGTCAGTGGTATTG 
500 
57 ˚C Internal 
F- CAAAGGAGGAGGCATTCGGA 
R- GGCAGGTCAGTGGTATTGCT 
139 
Ovine 
NF-κB 1 
BC153232.1 55 ˚C External 
F- CTATGACAGCAAAGCCCCCA 
R- GCCATACGTGGGGAATCCAT 
529 
55 ˚C Internal 
F- CCTCTGTGTTCGTGCAGCTT 
R- TACCACCGCCAAAACTGTCC 
153 
Ovine 
MAPK14 
NM_001142894.1 55 ˚C External 
F- CGAGCGTTACCAGAACCTGT 
R- TGTCGAGCCAGTCCGAAATC 
459 
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57 ˚C Internal 
F- GTTACCAGAACCTGTCCCCG 
R- ACCGCAGTTCTCTGTAGGTTC 
153 
Bovine/ 
Ovine 
SOCS3 
NM_174466.2 
(Bovine) 
XM_004013097.1 
(Ovine) 
55 ˚C External 
F- CTCAGCGTCAAGACCCAGTC 
R- CTAAAGCGGGGCATCGTACT 
447 
57 ˚C Internal 
F- GCGAGAAGATCCCTCTGGTG 
R- TGGTCCAGGAACTCCCGAAT 
148 
Bovine/ 
Ovine 
BDNF 
NM_001046607.1 
(Bovine) 
XM_004016358.1 
(Ovine, transcript 
variant 1) 
XM_004016359.1 
(Ovine, transcript 
variant 2) 
 
55 ˚C External 
F- CCATGAAAGAAGCCAACCTC 
R- TTGCACTTGGTCTCGTAGAA 
511 
57 ˚C Internal 
F- TCGTCGTTGGCTGACACTTT 
R- TCGCGGCATCCAGGTAATTT 
193 
Bovine  
Trk-B 
NM_001075225.1 55 ˚C External 
F- AAGCAAATCTCTTGTGTGGC 
R- TTACCACCACAGCATAGACC 
529 
57 ˚C Internal 
F- AATCTCCAACCTCAGACCAC 
R- ATTGTTCATGTGAGTGGGGT 
191 
*Annealing temperature 
4.4.4 Quantitative RT-PCR 
For the majority of the genes studied in this chapter, home made master mix was used for 
the quantitative RT-PCR. This contained the optimal concentration of essential reagents, 
(Invitrogen) including 10X buffer, 3mM MgCl2, 0.2mM dNTPs, and 10X SYBR green, primers 
(0.16μM per primer), 0.5U Platinum Taq DNA Polymerase (Invitrogen) and water in a 15μl 
reaction. Quantitative RT-PCR was performed on an iCycler iQ real-time PCR detection 
system (Bio-Rad). 
The expression of reference genes (GAPDH and ATPase) were determined in the same 
samples for all the genes and in home made RT-PCR reagents when necessary. 
Thermal cycling conditions and methods of data collection are described in Chapter 2. 
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4.4.5 Statistical analysis 
The statistical analyses were kept consistent throughout the study (see Chapter 2). 
Probability values of P < 0.05 were considered statistically significant between genotypes 
and ages. Levels of significance are indicated as *, P < 0.05 ; **, P < 0.01. 
4.3.6 Western blotting analysis 
4.3.6.1      Protein extraction 
The frontal, parietal and occipital lobes of the most medial slab of each 6, 9 and 18 month 
old CLN6 affected brains were dissected for SOCS3 protein detection. SOCS3 is a cytoplasmic 
protein and readily soluble in detergent free buffer (Park et al, 2014). Total soluble protein 
fractions were extracted by homogenising 300mg of grey matter from the frontal, parietal 
and occipital corticies in 1.2ml of extraction buffer (20mM Tris-HCl, pH7.5; 1mM EDTA, 5mM 
MgCl2) containing phosphatase inhibitors (0.1 NaF, 1mM β- glycerol phosphate, 1mM 
Na3VO4) and protease inhibitor cocktails (Roche Diagnostics, IN, USA), using a D130 
homogeniser (LabServ, Ireland). Protein storage and concentration measurements are as 
described in Chapter 2.  
4.3.6.2      Protein electrophoresis and transfer 
As described in Chapter 2. 
4.3.6.3      Western blotting analysis 
Western blotting was also used to monitor expression of proteins in the brain homogenates 
from selected regions at different ages. The optimal antibody concentration was initially 
determined on protein extracted from an 18 month-old affected animal and a healthy 
counterpart. The specificity of immunoreactivity of the antibody was observed by a band at 
the expected molecular weight. Mouse anti-human GAPDH (1:25000, monoclonal, Bio-Rad) 
was selected as the loading control. The concentration of rabbit anti-human SOCS3 primary 
antibody (1:1000, polyclonal, Abcam) was diluted in 3% blocking buffer (3% bovine albumin 
serum in TBST) and relevant secondary antibodies were applied. Immunoblotting, washing 
and developing of the blots were as per described in Chapter 2.  
Initial immunoblotting for SOCS3 showed specificity for SOCS3 and did not produce spurious 
bands that would interfere with GAPDH detection. Therefore blots stained for SOCS3 were 
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washed in TBST, then incubated with GAPDH antibodies followed by biotinylated secondary 
antibodies and ExtrAvidin peroxidase. 
4.3.7 Immunohistochemistry 
4.3.7.1      Tissue collection and processing 
Brain tissue from affected sheep aged 2, 6 and 24 months and age matched controls were 
used. Methods of perfusion fixation and tissue sectioning are elaborated in Chapter 2.  
Mesenteric lymph nodes from animals infected with the parasitic gastrointestinal nematode 
Trichostrongylus colubriformis were paraffin wax-embedded and 5μm sections serially cut 
from each block and mounted on superfrost plus glass slides (Gribbles Veterinary Pathology, 
Christchurch, New Zealand). These lymph node samples were kindly donated by Dr Andy 
Greer and Andrea Hogan (Faculty of Agriculture and Life Sciences, Lincoln University), and 
were shown to have high CD4+, CD8+ T cell counts by flow cytometry. These lymph nodes 
were processed for use as positive control tissues for CD4+, CD8+ expression. 
4.3.7.2      Immunohistochemistry 
Antibodies used were mouse anti-ovine CD4 (1:50, monoclonal, AbD Serotec, USA), mouse 
anti-ovine CD8 (1:50, mococlonal, AbD Serotec) and rabbit anti-ovine IgG (1:500, polyclonal, 
AbD Serotec). The CD4 and CD8 stainings were performed on mesenteric lymph nodes.  
Paraffin embedded lymph node sections were de-waxed and re-hydrated by washes of 
xylene and a diluted alcohol series: 2 washes in xylene, 5 min per wash; 2 washes in 100% 
ethanol, 3min per wash followed by 95%, 70% and 50% alcohol washes, 3min per wash, and 
a final 3min wash in water. Subsequently, the sections were immunostanined. All 
experimental sections were subjected to an antigen retrieval process. The tissue sections 
were incubated overnight in 0.1M sodium citrate buffer, pH 4.5, at 4°C, then transferred to 
6-well plates, containing 10ml of fresh buffer per well, and irradiated in a household 
microwave oven at 650W for 30s. After cooling to RT, sections were blocked for 30 min with 
1% H2O2 in PBST to quench endogenous peroxide activity and for 60 min in 15% NGS in PBST 
to remove non-specific tissue antigens. All steps were followed by three washes in PBST. 
Sections were then incubated with primary antibodies, overnight, 4°C, diluted in 10% normal 
goat serum (NGS) in PBST (PBS, pH7.4, containing 0.3% Triton X-100). Negative control brain 
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sections in which the primary or secondary antibodies were omitted, were included on the 
same incubation plate. 
Secondary and tertiary antibody incubations and colour development were shown as 
described in Chapter 2.   
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Pro-inflammatory (IL-1β, TNF-α) and anti-inflammatory (TGF-β, IL-10) cytokine expression 
from animals aged from 6 to 24 months were analysed and discussed in Barry (2011). In 
summary of results obtained by Barry (2011), TNF-α, IL-1β, TGF-β and IL-10 expressions 
increased in the affected animals compared with the controls at all ages analysed, including 
6 months, well before clinical disease is evident. However, they followed a different 
expression patterns with disease progression in terms of copy numbers and fold increases. 
Steady increases of IL-1β and TGF-β expression were observed while TNF-α and IL-10 
expressions increased at 6 months followed by a slight decrease at 9 months and peaked at 
18 months. They subsequently reduced but remained significantly high at 24 months (Fig 
4.2).  
No significant difference in expression was found between any of the cytokines in the 
frontal, parietal and occipital brain regions of the control samples or between the affected 
brain regions at any ages. There was a lack of activation of cytokine expression at 2 months. 
4.4.2 Gene expressions of transcriptional factors responsible for pro-inflammatory 
cytokine expressions 
Experimental animals, methods, and statistical analyses were consistent with the previous 
study (Barry, 2011) to provide a consistent map of the neuroinflammatory pathway 
regulated by the selected mediators. 
4.4.2.1 NF-κB1 
NF-κB 1 was expressed in control animals at all the ages at a low copy number (Fig 4.3). 
Expression did not vary between regions in either the control or affected animals and the 
pattern was similar between the control and affected animals at the ages of 2, 6 and 9 
months. Significant differences in expression became apparent at 18 months and 24 months 
(P<0.01). Dramatic increases of 5 fold were observed in the affected animals at 18 months 
and of 4 fold at 24 months, reaching copy numbers of 3.9x104 copy/µl cDNA (1µl cDNA 
=22.2ng mRNA) at 18 months and 1.7x104 copy/µl cDNA at 24 months (Table 4.2). The 
controls had a mean copy number of 7.9 x103 copy/µl cDNA at 18 months and 4.2 x103 
copy/µl cDNA at 24 months. 
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4.4.2.3 JAK2/STAT1/STAT3 
The expression of cytokine associated signal transducers, JAK/STAT, did not vary between 
regions (Fig 4.5). The expression varied between the signal transducers. Basal mRNA 
expression of JAK2, STAT1 and STAT3 were present in the control animals at all ages with 
slight fluctuations between the different ages. In the affected animals, although JAK2 
expression showed a trend of increase in the affected animals, but the expression was highly 
variable at the age of 6, 9, 12 and 18 months and only became significant at 2 fold at 18 
months (Fig 4.5; Table 4.4, control mean, 5.5x103 copy/µl; affected mean, 1.2x104 copy/µl). 
The expression of STAT1 was not significantly different between affected and control 
animals at 2 and 6 months but then showed a significant 3 fold increase in the affected 
animals at 9 months (Table 4.4, control mean, 1.7x104 copy/µl cDNA; affected mean, 5.5x104 
copy/µl cDNA) and a 5 fold change at 18 months (control mean, 1.5x104 copy/µl cDNA; 
affected mean, 7.7x104 copy/µl cDNA), and decreased at 24 months (control mean, 9.2x103 
copy/µl cDNA; affected mean, 3.8x104 copy/µl cDNA).  
Expression of STAT3 was similar in the control and affected animals at the age of 2 months, 
after which it became different, from 2 fold at 6 months (control mean, 6.0x104 copy/µl 
cDNA; affected mean, 1.2x105 copy/µl cDNA) to 4 fold at 18 months (Table 4.4, control 
mean, 8.5x104 copy/µl cDNA; affected mean, 3.5x105 copy/µl cDNA) followed by a decline to 
3 fold at 24 months (control mean, 5.9 x104 copy/µl cDNA; affected mean, 2.0 x105 copy/µl 
cDNA).  
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Figure 4.5 Quantitative PCR analysis of JAK2 (A), STAT1 (B) and STAT3 (C) mRNA 
expression, in the cortex of CLN6 affected and age matched control animals 
at 2, 6, 9, 18 and 24 months of age. Minimal control expression remained 
unchanged with age. 
A. JAK2 expression in the affected animals remained similar to the expression in the 
controls at 2 months. The expression in the affected animals increased over controls, 
but was only significant at 18 months. 
B. STAT1 expression in the affected animals increased from 6 months to 18 months and 
decreased at 24 months. Expression in the control animals was stable and at low 
copy numbers at all ages.  
C. STAT3 expression in affected animals was increased at 6 months, more so at 18 
months then declined at 24 months. 
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Table 4.4  Fold changes of JAK2, STAT1 and STAT3 
Gene of Interest Age 
(months) 
Fold change in comparison 
with the age-matched controls 
Statistical 
significance  
JAK2 2-9 - - 
18 2 * 
24 - - 
STAT1 2-6 - - 
9 3  * 
18 5 ** 
24 4 * 
STAT3 2-6 - - 
9 2 * 
18 4 ** 
24 3 * 
*-, not significantly different; *, <0.05; **, <0.01 
4.4.3 Gene expression of suppression of pro-inflammatory cytokines 
4.4.3.1 Quantitative RT-PCR of SOCS3 
Expression of SOCS3 in the affected animals was elevated as early as 2 months of age, 
increased progressively from 2 to 9 months and multiplied dramatically at 18 months (Fig 
4.6). Expression in the affected animals declined sharply at 24 months but remained 
significantly higher than that in the age-matched controls. The lowest expression level in the 
affected animal was 360 copy/µl cDNA, whereas the matched control was below 100 copy/µl 
cDNA, while as many as 5.1x104 copy/µl cDNA were found in 18 month-old affected animals. 
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Table 4.6  Fold change of BDNF and Trk B 
Gene of Interest Age (months) Fold change in comparison 
with the age-matched 
controls 
Statistical 
significance*  
BDNF 2-24 - - 
Trk B 2-9 - - 
18 3 ** 
24 2 * 
*-, not significantly different; *, <0.05; **, <0.01 
BDNF expression did not vary between the brain regions, ages and genotypes (Fig 4.8; Table 
4.6).  
The expression of the BDNF receptor Trk B in the control sheep was similar in all brain 
regions of all ages (Fig 4.8; Table 4.5). The mean expression of Trk B in the controls was 
around 1x105 copy/µl cDNA while that BDNF was 5000 copy/µl cDNA and the expression 
pattern mimicked BDNF expression. In contrast, Trk B expression in the affected animal 
showed little similarity to that of BDNF. It was not significantly different from the controls at 
the age of 2, 6 and 9 months, but increased three times more than age-matched controls at 
the age of 18 months (control mean 1.6x105 copy/µl copy/µl; affected mean 4.3x105 
copy/µl). Expression of Trk B decreased from 18 months to 24 months but was still almost 
twice that in the controls at 24 months. 
4.4.5 Blood-brain-barrier breach 
A disruption of the BBB would be indicated by IgG deposition within cells in the CNS and 
infiltration of lymphocytes into the CNS. This can be detected by the immunoreactivities of 
IgG and cell surface markers of lymphocytes. 
4.4.5.1 Immunohistochemical staining of lymphocytic markers 
The possibility of BBB breaches in the CLN6 affected brains at advanced stage were 
investigated by staining for the lymphocytic markers for CD4 (T helper cells) and CD8 (T 
cytotoxic cells) (Fig 4.9). Lymph nodes with high lymphocytic cells counts from parasite 
infected sheep were immunostained as positive controls for the lymphocytic markers. 
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Analyses of these sections revealed high numbers of cells immunoreactive to CD4 and CD8 in 
lymph nodes infected by parasites (Fig 4.9 B; Fig 4.10 B). No immunoreactive cells were 
found within the brains (Fig 4.9 D; Fig 4.10 D).  
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Figure 4.9 Immunohistochemical staining of CD4 in a control lymph node (A) a 
parasite-infected lymph node(B) a control cortex at 18 months (C) and a 
CLN6 affected cortex at 18 months (D). Scale bar represents 100μm. The 
parasite-infected lymph node showed evident cellular staining. Some 
predicted anatomical structures of lymph were depicted as CA capsule; F 
follicle; P paracortex; and R reticular fibre. 
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Figure 4.10 Immunohistochemical staining of CD8 in a control lymph node (A) a 
parasite-infected lymph node(B) a control cortex at 18 months (C) and a 
CLN6 affected cortex at 18 months (D). Scale bar represents 100μm. The 
parasite-infected lymph node showed evident cellular staining. Some 
predicted anatomical structures of lymph were depicted as AT adipose tissue; 
CA capsule; F follicle; P paracortex; SS subcapsular sinus; and T trabecula. 
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4.4.5.2 IgG deposition in the CLN6 affected brain 
IgG deposition in the 18- month- old CLN6 affected brains was examined by staining for 
heavy and light chains of ovine IgG. Perivascular immunoreactivity of IgG was evident in the 
control and affected brains (Fig 4.11 A, B) and not found in sections omitting the IgG 
antibody (Fig 4.11 C). No immunoreactivity was found within the CNS.   
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Figure 4.11 Immunoreactivity of IgG in cortex from the control and affected animals at 
18 month. Control cortex at 18 months (A), CLN6 affected cortex at 18 
months (B), for a negative control, IgG antibody was omitted in the CLN6 
affected section (C). 
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4.5 Discussion 
4.5.1 The cytokine expression profile at 2 months 
The selected ages marked the timepoint at which the important pathological features during 
diease progression (Section 2.1; Fig 2.2). Activated glial cells were evident in the affected 
sheep brain perinatally, marking an early activation of neuroinflammation (Oswald et al, 
2005; Kay et al, 2006). Neurodegeneration, predicted by glial activation and reflected by 
changes in neuron populations, initiates at 6 months. Clinical signs associated with visual 
impairment and behavioural change became obvious at 9 months. Advanced disease reflects 
the loss of vision, coincided with atrophy of the occipital cortex and loss of photoreceptors in 
the retina at 18 months. The brain is severely atrophied and little neurons remained at 24 
months.      
Aberrant pro- and anti-inflammatory cytokine expression is often related to the 
development of neuroinflammation and progression of disease (Benveniste, 1998). Glial cells 
are the major immune regulatory cells in the CNS, and they most likely stimulate neurons 
and other glial cells or infiltrate lymphocytes to produce cytokines (Szelényi, 2001). 
Cytokines could be released as “danger” signals that trigger an immune response (Allan & 
Rothwell, 2001). The study of expression of cytokine profiles could provide an insight into 
how these molecular cues stimulate and/or sustain an immune response in the CLN6 brain. 
A previous study demonstrated an early elevation of pro-and anti-inflammatory cytokine 
expression at 6 months, at the initiation of neuroinflammation (Barry, 2011). When these 
data for all four cytokines are supplemented by 2 month expressions, it became apparent 
that the expression of cytokines correlates with the initiation of neurodegeneration at 4-6 
months of age. The expression however does not correlate with the initiation of glial 
activation, which began earlier, indicating that the cytokine expression is a consequential 
event (Fig 4.2). 
Other inflammatory studies have also reported that the cytokine expression followed glial 
activation. TGF-β is expressed in activated astrocytes, microglia and oligodendrocytes and 
can induce its own gene in an autocrine manner in these cells (Benveniste, 1998; Szelényi, 
2001; Spittau et al, 2013). Most studies described the induction of TGF-β expression or its 
receptors upon glial activation, suggesting TGF-β expression is a consequential event of glial 
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activation (Mitchell et al, 2014; Pál et al, 2014; Sugimoto et al, 2014). Also, neurons and 
microglia were reported to produce IL-10 upon glial activation (Szelényi, 2001).  
There is a possibility of early activation of cytokines prior to glial activation in the absence of 
changes in transcription. Cytokine activation can arise from post- translational modification 
of existent cytokines rather than increased transcription. Pre-existing pro-cytokines may be 
sufficient for the production of active signals at the early ages of the disease. Both TNF-α and 
IL-1β have pro-forms, that remain cytoplasmic until they are cleaved enzymatically by the 
TNF-α converting enzyme matrix metalloprotease and matrix metalloproteinase respectively 
(Martinon & Tschopp, 2004; Amantea et al, 2007; McCoy & Tansey, 2008). The proteolytic 
enzymes of the pro-TNF-α and pro-IL-1β were reported to be responsible for the secretion of 
pro-inflammatory cytokines upon inflammation (Amantea et al, 2007; Lee et al, 2014). In a 
study of juvenile NCL/CLN3, the primary microglia isolated from CLN3∆ex7/8 mutated mice 
showed an intrinsic hyper-response to the pro-inflammatory cytokines as well as to the 
inflammatory stimuli released from the JNCL brain cells (Xiong & Kielian, 2013). The hyper-
response involved the “inflammasome”-caspase 1 activation which led to subsequent 
secretion of IL-1β (Xiong & Kielian, 2013).  
The roles of the upregulation of these cytokines up-regulation are not very clear. IL-10 
receptors have been expressed in a variety of cells in murine and human CNS in basal 
conditions and after injury. Cells with receptors include neurons, microglia, astrocytes and 
oligodendrocytes (Ledeboer et al, 2002; Cannella & Raine, 2004; González et al, 2009; Lim et 
al, 2013; Norden et al, 2014), suggesting that IL-10 may be capable of acting on a broad 
range of cells. IL-10 and TGF- β are proposed to be anti-inflammatory cytokines but they did 
not seem to suppress the neuroinflammation in spite of increased expression in the CLN6 
brain (Fig 4.2). One explanation is that any anti-inflammatory action of IL-10 and TGF-β in the 
affected brains may have been limited because of the dramatic intensity of other 
inflammatory responses (Barry, 2011). TNF-α and IL-1β expressions have been suggested to 
be the fast response cytokines prior to neuronal death in rodents (Buttini et al, 1994; Liu et 
al, 1994; Wang et al, 1994). Clinical studies have shown correlation between the 
concentrations of inflammatory cytokines and the severity of the disease (Griffin et al, 1994; 
Krupinski et al, 1996; Doty et al, 2015). However, it is difficult to speculate the role of these 
cytokines in neuronal damage in CLN6 brains since the signalling network of cytokines is 
complex and the cellular locations of cytokine expression are not determined in this study.  
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Despite the reports of the cellular location of cytokines, one possibility is that mainly in glial 
cells, the expression of cytokines does not follow the regional pattern of glial activation (Fig 
4.2). In fact, no regional differences were observed in the gene expressions investigated in 
the present study (Fig 4.2, 4.3, 4.4, 4.5, 4.6 and 4.8). Previous studies had demonstrated the 
selective survival of the GABAergic interneuron under the influence of glial activation while 
the gonadotrophin-releasing hormone secreting neurons degenerated in the absence of glial 
activation, suggesting that the functionality and connectivity of the cells are better 
determinants of neuronal survival than cell phenotypes (Oswald et al, 2006; Kay et al, 2011). 
Subpopulations of neurons in some brain regions may be more sensitive to uncontrolled 
inflammatory signalling than others and other determining factors such as temporal changes 
in the molecular cues may add to the neuronal stress. 
4.5.2 NF-κB 1 
The time course of the ubiquitous form of NF-κB 1 gene expression showed its up-regulation 
is likely to be associated with elevation of cytokine expression, serving a role in amplifying 
neuroinflammation at the end stage of disease, but follows rather than leads to cytokine 
expression. 
Although the change of NF-κB 1 expression only became apparent at 18 and 24 months (4.8 
and 4.1 folds, respectively, Fig 4.3), the amplitude of increase was high. Up-regulation of NF-
κB 1 corresponded with peak elevation of TNF-α expression at age of 18 months, which is 
known to induce NF-κB in murine macrophages (Collart et al, 1990) and human 
macrophages (Hohmann et al, 1990). Though NF-κB 1 expression declined at 24 months, a 4 
fold increase was sustained. IL-1β expression is also reported to activate NF-κB to induce a 
positive autoregulatory loop in some human cell lines (Hiscott et al, 1993). IL-1β was 
increased 7.2 fold at 24 month of age (Barry, 2011). NF-κB 1 did not appear to associate with 
the increase, therefore, IL-1β may not be the primary target of NF-κB.  
The ability of NF-κB to respond to a signal does not require transcriptional activation (Ghosh 
et al, 1998) and the possibility of an early activation of NF-κB cannot be excluded. The 
subunit p50 is a post-translational product of a larger product (p105) which encoded by the 
gene NF-κB 1. The p105 is exclusively cytosolic, attributed to masking of the nuclear 
localisation signals (NLS) by the C-terminal ankyrin-repeat region (Henkel et al, 1992). This 
indicates another possible level of control of NF-κB activation. Pre-existing p105 could be 
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processed rapidly upon stimulation and activated without active transcription. Therefore, 
NF-κB could be activated without more being translated. Moreover, the duration of NF-κB 
activation is not known since it is correlated with both the synthesis and degradation of NF-
κB inhibitors (IκB proteins). IκB binds to heterodimers (i.e. p50/p65), thereby masking its 
nuclear localization sequence and inhibiting its DNA-binding activity (Ghosh et al, 1998). The 
differential degradation rates of free and bound IκB proteins were proposed to have an 
impact on constitutive NF-κB activity while the NF-κB activity also plays a role in 
transcriptional regulation of these inhibitors to control its own steady-state activity (O’Dea 
et al, 2007).  
4.5.3 MAPK14 
Expression of the p38α gene, MAPK14, only showed siginificant increase in the advanced 
disease, indicating MAPK14 expression is not affected in disease progression (Fig 4.4). 
However, this may not fully represent the activation of the p38α MAPK signalling pathway in 
the disease progression, since again activation of such pathway greatly relies on post-
translational modification. p38α MAPK is activated when threonine and tyrosine in the 
activation loop are phosphorylated (Huang et al, 2009). The phosphorylated substrate of 
p38α MAPK or phosphorylated forms of p38α MAPK are markers for p38α MAPK activation 
(Lo et al, 2014). It is also reasonable to consider the impact of the down-regulatory 
mechanism by protein phosphatases that may also play a role in the dynamic regulation of 
MAPK14 expression (Hargrove & Schmidt, 1989). 
The brain specific isoform p38β may be preferentially activated in the CLN6 affected brain, 
though it is potentially functionally redundant in the presence of p38α (Section 4.3.3). 
Nevertheless, p38β demonstrated substrate preference in vitro. For instance, activating 
transcriptional factor 2 (ATF2) was shown to be better phosphorylated by p38β, indicating a 
different regulatory mechanism of p38β on the downstream targets (Jiang et al, 1996). 
Therefore, p38β may be selectively activated to act on specific substrates.  
4.5.4 JAK2/STAT1/STAT3 
Similarly to the other transcriptional factors, JAK2/STAT1/STAT3 were not up-regulated at 
early stage of the disease progression (Fig 4.5). This indicates that the pathway is not likely 
causative. The change of JAK2 expression was barely 2 fold at terminal disease. STAT1 and 
STAT3 expression increased in the affected animals at 9 months, and peaked at 18 months. 
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Expression of all these genes decreased but remained higher than the controls at 24 months. 
The high level of variation indicate evident differences in expression between biological 
replicates and leads to doubts that the apparent up-regulation of these genes are truly 
biologically important in the pathogenesis.  
There were high levels of variation between biological replicates in JAK2 expression in both 
genotypes and in the affected animals for STAT1 and STAT3. Large differences between PCR 
replicates and biological replicates could occur in quantitative real-time PCR, due to the 
chemistry of PCR reaction when genes are expressed in low copy numbers (<1000 starting 
copy) (Peccoud & Jacob, 1996; Karrer et al, 1995). This, in theory, could partially result from 
the reduced collision frequency of primers and templates thereby reduced chances of 
contact between the primers and the respective templates (Ruano et al, 1991). JAK2, STAT1 
and STAT3 had starting copies that are more than 1000 and the variation only represent the 
differences between biological replicates, not PCR replicates. Thus, technical limitations do 
not account for the large variation.  
It is not surprising that the affected animals showed slightly higher expression since the 
product of the mutated CLN6 may cause a general metabolic disturbance in cells and affect 
transcriptional expression. This should affect all the affected animals equally. Therefore, the 
differences of expression between the biological replicates may not be disease-related and 
may arise from the responses of the individuals.  
In addition, the variable expression between biological replicates could well be a sampling 
issue. The expression of these genes could be variable in cell types and brain regions and this 
has been demonstrated in Chapter 3.  
Activation of JAK/STAT is likewise post-translational, by phosphorylation of JAK2 tandem 
tyrosine residues in an activation loop and STAT1 and STAT3 on serines and tyrosines 
(Hornbeck et al, 2012). Again like NF-κB, the JAK/STAT pathway can be activated without 
active transcription.  
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4.5.5 SOCS3 
4.5.5.1         SOCS3 expression is associated with an irregular immune response  
The up-regulation of SOCS3 (Fig 4.6; Table 4.5) in the CLN6 brains are not understood since 
the primary up-stream regulators of SOCS3, IL-10 (Fig 4.2) and STAT3 (Fig 4.5) were not up-
regulated prior to its up-regulation at 2 months. The role of SOCS3 is also ambiguous in 
relation to its possible function in the CLN6 brain. 
The early response of SOCS expression may indicate an inhibition of glial activation (Fig 4.6). 
Immunoregulatory roles of SOCS3 have been proposed to suppress activation of immune 
cells in mice (Lee et al, 2002; Croker et al, 2003; Panopoulos et al, 2006) and human (Hörtner 
et al, 2002) at an developmental stage for cell differentiation such as haematopoiesis 
(Panopoulos et al, 2006; O’Shea & Murray, 2008). G-CSF, a cytokine, in part stimulates 
maturation and exit of neutrophils from bone marrow (Eyles et al, 2006) via its receptor G-
CSFR, activates STAT3 and triggers SOCS3 expression (Lee et al, 2002; Hörtner et al, 2002; 
Croker et al, 2003). The SOCS3 may then down-regulates the signalling pathway via inhibiting 
G-CSFR and STAT3, resulting in a reduction of neutrophils (Lee et al, 2002; Hörtner et al, 
2002).  
SOCS3 expression was proposed to have different effects depending on the cell types in 
mice. SOCS3 expression in glial cells appears to have an anti-inflammatory role. In 
astrocytes, IFN-β induces the expression of SOCS3 in a STAT3 dependent manner (Qin et al, 
2008). Disruption of SOCS3 production leads to enhanced production of chemokines that 
promote migration of microglia and T cells (Qin et al, 2008). The mechanism of SOCS3 
mediated anti-inflammation has been studied. IL-10/IL10R/STAT3 induced SOCS3 expression 
competes with the STAT3 binding site on the IL-6 receptor (gp130), thus preventing the 
recruitment of the down-stream signalling complex (Section 4.3.4). IL-10 induced SOCS3 
expression was reported to down-regulate inflammatory genes, partially via inhibition of IL-6 
receptor binding (Qin et al, 2006). On the other hand, SOCS over-expression in neurons have 
been suggested to have a deleterious effect on neuronal survival. Evidence suggests that 
over-expression of SOCS3 reduces neural survival and deletion of SOCS3 promotes neural 
repair (Miao et al, 2006; Smith et al, 2009a; Sun et al, 2011; Park et al, 2014). 
SOCS3 appears to have both pro- and anti-inflammatory actions often associated with STAT3 
activation. However, STAT3 was not up-regulated prior to SOCS3 activation in the early 
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disease (Fig 4.5; 4.6), suggesting either a transient activation of STAT3 or STAT3- 
independent activation. SOCS3 is known to primarily and negatively regulate JAK/STAT1/3 to 
restore the balance of the molecular environment. Supposedly, a positive feedback triggered 
the SOCS3 expression and it is unlikely to be the JAK/STAT pathway, because that pathway 
did not seem to be activated as dramatically as SOCS3 (Table 4.4; Fig 4.5). Studies have 
found SOCS3 can be induced by growth factors, growth hormone, leptin and insulin 
(Bjørbaek et al, 1998 in vivo, mice; Cacalano et al, 2001 in vitro, humans; Peraldi et al, 2001 
in vitro, mice), suggesting SOCS3 expression can be induced via means other than the 
classical JAK/STAT pathway.  
A mutation in CLN6 may have an effect on the regulation of SOCS3 expression, but without 
knowing the exact function of CLN6, it is difficult to rationalise the correlation. IL-10 is 
proposed to be implicated in up-stream SOCS3 signalling (Qin et al, 2008), but did not show 
parallel up-regulation in early disease progression, adding to the difficulty of interpreting the 
SOCS3 elevation.   
4.5.5.2       SOCS3 expression and microglial phenotype 
SOCS3 has been proposed to be a marker for polarised microglia in response to stress (Chhor 
et al, 2013). Activated microglia are thought to be able to adopt distinct phenotypes and 
switch between phenotypes, depending on the disease type and the progression (Perry et al, 
2010). Their expression of the cell surface receptors and release of soluble factors in 
response to chemical or cell specific cues are proposed to distinguish the different 
phenotypes (Perry et al, 2010; Chhor et al, 2013). Similarly to macrophages, microglial 
phenotypes can be classified as M1 (cytotoxic) and M2 (immunoregulatory). M2 is further 
divided into M2a (repair and regeneration), M2b (immunoregulatory) and M2c (acquired –
deactivating) (Chhor et al, 2013). However, the morphology of microglia do not reflect 
changes of their phenotype (Perry et al, 2010). The surface receptors and secretion of 
molecules differs between phenotypes. SOCS3 was recognised to be up-regulated with IL-1R, 
a known marker for M2b, and was proposed to be a novel marker for M2b (Chhor et al, 
2013). The early response of SOCS3 in the CLN6 affected brain may due to a change of 
microglial phenotype. The longitudinal study on glial activation previously used MHC II and 
GSB4 to label activated microglia (Oswald et al, 2005). There is a lack of information as to 
whether MHC II and GSB4 are able to differentiate phenotypic changes of microglia. 
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Nonetheless, they detected activated microglia as early as 12 days in the CLN6 affected 
parieto-occipiral cortex (Oswald et al, 2005). This microglial activation is region-specific and 
is not correlated with a general up-regulation of SOCS3 in the cortex (Fig 4.6).  
4.5.5.3         SOCS3 protein detection 
Expression of SOCS3 protein was investigated by Western blotting (Fig 4.7). The protein 
expression increased dramatically in the affected animals at the ages of 9 and 18 months, 
correlating with the elevation of gene expression (Fig 4.7). This was not observed at earlier 
ages, perhaps because the low abundance and short protein half-life made it difficult to be 
detected. 
There is little expression of SOCS3 protein in the control sheep. It was difficult to detect any 
signals when 25µg of soluble protein was loaded. Doubling amount of loading and longer 
exposure of films were required to produce visible signals. Studies have found features of 
SOCS3 in cells that either interact with elongin B/C, or bear phosphorylated tyrosine residues 
Tyr204 and Tyr221 (Zhang et al, 1999; Haan et al, 2003). The latter form has been shown to 
enhance proteasome-mediated degradation of SOCS3 (Haan et al, 2003). It has also been 
suggested to support cytokine and growth factor signalling, such as by IL-2, EPO, EGF and 
PDGF (Cacalano et al, 2001). In addition, SOCS3 has a PEST motif in its SH2 domain which 
appears to mediate non-proteasomal degradation (Babon et al, 2006). In spite of a positive 
feedback role of the phosphorylated SOCS3 in signal transduction, post-translational 
modifications seem to aim for a fast degradation of SOCS3, suggesting a high turn-over of 
the protein. The short half-life of SOCS3 may cause difficulties for detection for the protein. 
SOCS3 mRNA expression is significantly higher at the ages of 2 and 6 months in the affected 
animals, however copy numbers are not high, suggesting that the protein concentrations 
may still not be sufficient for detection at those ages.   
4.5.5.4       SOCS3 mRNA and protein correlation 
Immunoreactive SOCS3 was only visible in the affected animals at 9 and 18 months, 
confirming the disease-related role of SOCS3 (Fig 4.7). That the affected frontal cortex did 
not show immunoreactivity at 9 months is likely because the amount of protein was not 
enough for detection (Fig 4.7). The significant fold change for SOCS3 was 21 and 74 at 9 and 
18 months respectively (Table 4.5). The intensity of the immunoreactive band appeared to 
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be much stronger at 18 months than at 9 months (Fig 4.7), indicating a parallel increase in 
protein expression. However the change of protein expression appeared to be more 
dramatic than the change of transcription between 9 and 18 months (Table 4.5; Fig 4.7). 
Correlations between mRNA transcription and protein translation as well as protein 
degradation could be subject to variable degrees of disruption when disease progresses. The 
transcriptional and translational machinery and protein degradation in cells may be less 
tightly controlled due to the severity of the disease. Observations of a widespread up-
regulation of all the genes towards the end stage of the disease at 18 months indicates an 
uncontrolled response. Presumably the correlation between mRNA and protein would 
become more discordant as disease progresses. Other possibilities could be involved, such as 
the samples were from the degenerative region that had higher concentration of the protein 
(Section 3.4.2; 3.4.3) and individual differences in protein expression between sheep.  
4.5.6 BDNF and Trk B 
BDNF did not appear to associate with disease progression but the affected animals do 
appear to have a large difference in expression at 2 months (Fig 4.8A). This difference was 
caused by one animal showing much higher expression. The same animal did not produce 
variable expressions for the other genes investigated. It is not clear what caused the 
variation of BDNF expression in this particular affected animal. Stimuli such as deprivation of 
light (which causes reduction of mRNA), electroconvulsive seizure, mechanical stimulation 
and physical exercise can physiologically alter BDNF expression (Castrén et al, 1992; Neeper 
et al, 1995; Rocamora et al, 1996; Dias et al, 2003). 
The difference in copy numbers and expression pattern were found between BDNF and Trk 
B. Differences are most likely attributable to the difference in localisation between these 
molecules. Expression of BDNF and Trk B did not appear to correlate precisely in cells and 
brain regions in adult mice and human (Murer et al, 1999; Tang et al, 2010; Marco-Salazar et 
al, 2014).  
The overall objective of this study was to probe whether intracellular vesicle sorting of BDNF 
and Trk B was interrupted by mutated CLN6. The relatively stable expression of BDNF in 
affected brains suggests that BDNF sorting may not be disrupted. The Trk B expression 
pattern in the affected animals resembled that of most of the genes investigated in that it 
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peaked at 18 months and declined in 24 months (Fig 4.8B), emphasising the possibility that 
there is a global metabolic dysfunction of cells at terminal disease. 
4.5.7 Sampling error  
The observation of immunostaining for mitochondrial proteins revealed a sampling problem 
associated with the uneven distribution of their expression (Section 3.4.2; 3.4.3). It should be 
recognised that the selected neuroinflammatory genes could be subject to the same 
sampling problem, since the same samples were used for the detection of mitochondrial 
genes. As all these genes showed a higher expression at late disease stages, it may mean 
there are changes in anatomical and cytoarchitectural structure in the CLN6 brains rather 
than an intrinsic cellular change in activities, except for SOCS3 which increased its expression 
when the brain remained intact at early developmental stages. However, SOCS3 protein and 
gene expression could be affected by sampling error in later disease progression.  
4.5.8 Activation of signalling pathway  
The uncertainty in the current study as to whether mRNA levels are reflective of protein 
expression and activation of the signalling pathway is difficult to answer. Statistical studies 
on the collection of genes and their corresponding proteins showed mRNA-protein 
correlation strength could vary between genes, indicating that mRNA levels are not 
necessarily reflective of protein expression (Östlund & Sonnhammer, 2012; Guo et al, 2008).  
Theoretical mathematical models for mRNA and protein induction is able to predict: 
“The concentration of protein at steady state equals the product of the rate constants 
for synthesis of mRNA and protein (ks1 and ks2) divided by the product of the rate 
constants for degradation (kd1, and kd2) and that the rate at which protein 
concentration changes depend on the rate constants for degradation of both the 
mRNA and the protein. This permits great flexibility in controlling induction kinetics for 
particular gene products, since their synthesis, translation, and degradation may be 
regulated co-ordinately to permit induction to be stable or transient or to amplify the 
final yield of protein.” 
-Hargrove and Schmidt, 1989 
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The mathematical model was built on the premise that mRNA and protein expression is 
correlated and the biological importance of such correlation. mRNAs of transcriptional 
factors are generally short-lived (Wang et al, 2002b; Yang et al, 2002; Sharova et al, 2009), 
suggesting that mRNA of transcription factors is sensitive to transcriptional regulation under 
stress conditions (Dey et al, 2015). Therefore, studies of mRNA levels of the transcription 
factors as a predictor of their functional protein expression may not be entirely invalid. 
Although the translational modification is significant in the activation of proteins, 
transcriptional regulation also plays a role in maintaining the steady-state level of a protein 
(Hargrove & Schmidt, 1989). Depletion of non-phosphorylated forms of a molecule in 
cytosolic pools is likely to trigger transcription of the molecules to sustain an overall level. 
Measurements of phosphorylated forms of the signalling molecules would be informative as 
to whether the signalling pathway is temporarily activated when the threshold of 
transcription is not reached. For instance, STAT3 may be temporally phosphorylated to 
trigger transcription of SOCS3 without changing the number of transcripts.  
4.5.9 Lymphocytic infiltration and IgG deposition 
Evidence of a BBB breach has been found in some murine NCL models and in one human 
case (Lim et al, 2007; Saha et al, 2012; Groh et al, 2013). However, a lack of immunostaining 
for lymphocytic markers in the CLN6 affected brain, and the lack of deposition of 
immunoglobulin (IgG) beyond the intravascular space, indicates that the BBB integrity is not 
disrupted in the ovine CLN6 affected brain (Fig 4.11). 
IgG staining revealed uptake of IgG into perivascular space, neurons, and occasional 
astrocytes in the entorhinal cortex and the hippocampus in human JNCL. CLN3-/- mice also 
showed neuronal uptake of IgG in the cortex and hippocampus. In controls of both 
experiments, IgG deposition was reported within the blood vessels (Lim et al, 2007). This 
observation could possibly arise from sample handling. An early investigation demonstrated 
that extravascular leakage leading to cellular uptake is dependent of the time between 
death and autopsy (Mori et al, 1991). Serum protein leakage could evolve from focal to 
diffuse patterns and also caused by mishandling of post mortem tissue (Mori et al, 1991). In 
the ovine brain, IgG deposition was only found in intravascular space regardless of 
genotypes, brain regions, and ages. The staining was evidently not an exclusive characteristic 
of the affected animals, indicating coagulation of the residual blood post mortem due to 
capillary action caused by the small size of the blood vessels in the brain.  
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Moreover, other data in Lim et al (2007) cannot adequately support the hypothesis of the 
BBB breach in the disease mechanism. Deposition of immunoglobulins, and infiltration of 
lymphocytes in the CNS was found in human JNCL autopsy material at terminal stage of the 
disease, thus does not indicate a pathogenic role of the BBB breach in disease progression. 
In the murine JNCL (CLN3-/-), the immunohistochemical and western blotting analyses of 
tight junction proteins, which facilitate a barrier function by maintaining tight junction 
integrity, did not reveal changes of expression (Lim et al, 2007). 
In another report regarding the BBB disruption of human INCL (PPT1), increased expression 
of matrix metalloproteinases (MMPs) found in one affected human brain, was thought to be 
potentially activated by cytokine released from the infiltrated lymphocytes (Saha et al, 
2012). This correlation was suggested based on a murine study (Saha et al, 2012). TH17 cells 
were found in the brain of Ppt-KO mice (INCL). In cell cultures, MMPs were increased in 
murine brain endothelial cells treated with IL-17A, which could normally be produced by 
TH17 cells. The assumption of this correlation is challenged by the lack of indication of 
infiltration of TH17 cells and of perturbation of the BBB in the INCL human brain (Saha et al, 
2012).  
Breaches of the blood-brain-barrier have been considered as a possible underlying 
mechanism for neurodegenerative diseases. Despite the fact that small animal models could 
be informative in understanding the mechanism of neurodegeneration, they do not 
completely recapitulate human disease, especially as the human brain has a more 
complicated anatomy and physiology. Research scientists often work in a reductionist way. 
For instance, human AD displays both amyloidopathy and tauopathy while small animal 
models were developed to focus on one or the other (Institute of Medicine, 2013). Studies of 
these animals are subjected to the constraint of their short life span, whereas the human 
disease occurs and evolves over years. Animal models with knock-out genes are not likely to 
replicate human disease, much less so when the diseases are caused by genetic mutations 
that may enable the production of protein that may retain partial or altered function that 
play a part in the pathogenesis. 
An adaptive immune response is considered to be a secondary response following the innate 
response initiated by glial activation. The development and severity of the secondary 
response may vary between species. For instance, SOD1 mice showed permeability changes 
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and microhaemorrhages that implied severe vascular damage in murine ALS while 
microbleeds were not observed in human ALS, regardless of regional hypoperfusion (Evans 
et al, 2013). Although there is a lack of preliminary data relating to the BBB disruption in 
human NCL, an alteration of the BBB cannot be completely precluded. The end-stage 
characteristics of cerebellar pathology of human CLN6 may not be seen in the affected sheep 
as the affected sheep may not live long enough (Oswald et al, 2005). Similarly, the BBB 
breach may be part of the pathogenic mechanism of human disease but the ovine model 
does not exhibit the BBB breach because the animals were sacrificed before natural death 
for humane reasons. Current clinical practice involving BBB imaging makes it possible to 
measure the BBB permeability (Veksler et al, 2014). A way forward is that non-invasive 
assessment of the human BBB integrity by MRI, which is able to directly investigate human 
cases in a timely manner and in large numbers, to characterise if a BBB disruption is present 
and consistent among NCL patients.  
4.6 Conclusion 
The study revealed that only SOCS3 changes are meaningful to the neuropathogenesis while 
changes in the other selected genes are possibly contributing factors, but do not directly 
cause the disease.  
It was not expected that the majority of the selected neuroinflammatory genes shared 
similar expression patterns in which expression increased between neurodegeneration 
initiation (6 months) to terminal disease (18 months) then declined in the severely atrophied 
and dying brain (24 months). The exception was SOCS3 expression, which was elevated as 
early as 2 months of age in parallel with the initiation of neuroinflammation. This suggests a 
general metabolic disruption of cells following glial activation rather than being causative. 
The cell types involved are not clear. Up-regulation of the genes could be inflated or 
underestimated depending on shifts in cell populations concomitant with the loss of neurons 
and the increase of glial cells. Measurements of mRNA in specific cell populations can be a 
future direction as could use cell-specific markers in conjunction with the endogenous 
references genes. 
Regional differences in gene expression were not found. Physiological functionality and 
interconnectivity determines the cell fate (Oswald et al, 2006, Kay et al, 2011). The 
contradictory roles of SOCS3 suggest the same molecule may have different actions 
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depending on the physiological functions of the cells. The intercellular signalling may be 
subtle, temporal and hard to be detected using the current post-mortem investigation.   
The SOCS3 elevation at 2 months is probably a genuine response as the cytoarchitecture 
remains intact. It is likely associated with a primary response. It is not understood what 
triggered the up-regulation. STAT3 is known to transcribe the SOCS3 gene, and may be 
temporally activated without a change of mRNA expression. However, the underlying 
mechanism of this elevation requires further investigation. 
There was no evidence of BBB disruption in the ovine CLN6 brain, suggesting the ovine 
model at 24 months does not reflect the terminal human pathology. However, the BBB 
disruption has not been proven to be a general pathology in human NCL. If the BBB 
disruption is part of the terminal pathology in human NCLs, any adaptive immune response 
that occurs at the terminal stage of the human disease may not be additive to the 
neuroinflammation but a sign of virtually dead brain. 
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impaired lysosomal degradation, successfully increased PGRN in the ER and Golgi network 
but not in the lysosome or autophagosome.  
Progranulin is also a secretory glycoprotein which can be detected in the blood and the CSF 
(Zhou et al, 1993; Van Damme et al, 2008). It is proteolytically cleaved by neutrophil 
proteases to produce smaller proteins, namely granulins (Petkau & Leavitt, 2014). The exact 
function of progranulin in the brain is unknown. Progranulin was consistently reported to be 
up-regulated in astrocytomas and in activated microglia, suggesting a role in 
neuroinflammation (Petkau & Leavitt, 2014). 
5.1.2.2      Progranulin and FTLD 
Progranulin attracted attention when it was discovered that heterozygous mutations in its 
gene, GRN, cause fronto-temporal lobar dementia (FTLD). The most common FTLD, FTLD-
TDP43, is characterised by pathological inclusions of a hyper-phosphorylated and 
ubiquitinated trans-activating DNA binding protein with a molecular weight of 43kDa (TDP-
43), and ubiquitin in cells in the cortex, hippocampus and corpus striatum (Cairns et al, 
2007). In general, the affected patients show symmetrical focal atrophy of the frontal or 
temporal lobes, or both, as well as occasional asymmetrical atrophy (Cairns et al, 2007). 
Clinical symptoms include frontotemporal dementia, dysfunction in semantic language 
(termed semantic dementia, SD), and speech impairment (termed primary progressive non-
Xuent aphasia, PNFA). Overlapping clinical phenotypes relate to neuropathologic lesions 
including motor neuron disease (MND)/amyotrophic lateral sclerosis (ALS) and Parkinsonism 
(Cairns et al, 2007). Heterozygous mutations in GRN result in losses-of-function that lead to a 
30% protein reduction and a 50% mRNA loss, suggesting a haplo-insufficient nature (Petkau 
& Leavitt, 2014).  
5.1.2.3 Progranulin and NCLs 
A recent report proposed that homozygous mutations of the progranulin gene (GRN) result 
in a new form of NCL, based on the resemblance of fingerprint inclusions and some 
phenotypic clinical symptoms observed in patients (Smith et al, 2012). NCL inclusions of 
similar morphology were found in GRN-/- mice (Ahmed et al, 2010; Petkau et al, 2012; Smith 
et al, 2012). In addition to other findings in regard to progranulin, it has been suggested that 
progranulin may be associated with lysosomal function (Gӧtzl et al, 2014). Firstly, 
progranulin was found to be endocytosed by neurons via the binding of sortilin, which is a 
transport receptor involved in the targeting of soluble lysosomal proteins (Braulke & 
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be activated by tyrosine-kinase-associated receptors, including toll-like receptors (TLRs) and 
cytokine receptors in immune cells such as T cells and dendritic cells (DCs). Upon activation 
by cytokines, the phosphotyrosine motifs (pYxxM) in the receptor tyrosine kinases recruit 
PI3K which induces conformational changes that activate the catalytic subunit. Activated 
PI3K then catalyses phosphatidylinositol-(4,5)-bisphosphate (PIP2) to phosphatidylinositol-
(3,4,5)-triphosphate (PIP3). Downstream PIP3 activates kinases, such as PDK1 and AKT/PKB 
to act on multiple cellular pathways.  
Neuroinflammation is marked by elevated cytokines and related signalling molecules, as 
shown in the previous chapter of this study. The immuno-regulatory function of the PI3K 
signalling pathway is implicated in the maintenance of proper adaptive immunity, self-
tolerance in lymphocytes and activation of autophagy (So & Fruman, 2012). Activation of the 
PI3K IA- Akt signalling pathway is thought to be pro-survival and anti-apoptotic via inhibition 
of apoptotic molecules such as GSK3β, Bcl-2 associated death protein (BAD), and forkhead 
transcription factor (FKHR) (Datta et al, 1997; Franke et al, 2003). Activation of Akt has also 
been shown to inhibit the formation of autophagosomes by phosphorylating downstream 
targets, including the mammalian target of rapamycin (mTOR). Regionally specific activation 
of PI3K IA in the parietal and occipital cortex was reported in the CLN6 ovine brain and was 
suggested to relate to the PI3K IA-GSK3β pathway (Kanninen et al, 2013), hence the 
activation of PI3K signalling may be associated with the mediation of cytokine signalling in 
neuroinflammation in the NCLs. Cytokine signalling, such as by IL-1, is mediated by activation 
of a receptor complex (IL-1R1, IL-1RAcP) and an adaptor molecule (MyD88), which lies 
upstream of PI3K (Viviani et al, 2004; Li et al, 2010). Meanwhile, IL-10 was also reported to 
be up-regulated by the PI3K signalling pathway (Tapia-Abellán et al, 2012).  
5.1.3.2        PI3K, autophagy and endocytic pathway 
There have been numerous indications of disturbances in the endosome–lysosome pathway 
and suggestions of problems with autophagy in NCLs. PI3K III is thought to mediate 
autophagy by forming a protein complex containing Beclin 1, a novel Bcl-2 interacting 
autophagic protein that is the mammalian homolog of the ATG6 gene in yeast promoting 
autophagy (Liang et al, 1999; Kihara et al, 2001). Although PI3K signalling has been reported 
to be impaired in CLN3 and CLN10 and proposed to be caused by autophagic stress (Cao et 
al, 2006; Walls et al, 2007; Chang et al, 2011), hyper-active autophagy is not a common 
feature of the large number of histological and ultrastructural studies of tissues from 
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patients and animal models (Palmer et al, 2013). Any alteration in PI3K signalling is more 
likely to be associated with the defective endocytic pathway.  
Some NCL proteins have been predicted to be components of GERL pathway, suggesting the 
pathway may be defective. Disturbed endocytosis and intracellular trafficking has been 
reported in NCL studies including CLN1, CLN2, CLN3, and CLN5, mostly in cell culture studies 
(Fossale et al, 2004; Kyttälä et al, 2004; Luiro et al, 2001; 2004; Kopan et al, 2004; Buff et al, 
2007; Saja et al, 2010; Mamo et al, 2012; Uusi-Rauva et al, 2012).  
There is evidence that showed inhibition of PI3Ks pathway impaired the targeting of 
procathepsin D from the trans-Golgi network (TGN) to the lysosomal compartment and 
resulted in intracellular accumulation of unprocessed procathepsin D in yeast and in 
mammalian cells (Davidson, 1995; Brown et al, 1995). In plant cells, inhibition of PI3Ks led to 
swelling and aggregation of late endosomes that consequently affected degradation of 
proteins (Takáč et al, 2012; 2013). In these studies, non-selective inhibition of PI3Ks by 
wortmannin and Y294002 did not reveal specific functions of different classes of PI3K in 
GERL pathways. 
Constitutive generation of PI(3)P by PI3K III is conserved from lower eukaryotes to plants and 
mammals, and is acquired as a lipid component of the endosomal compartment (Engelman 
et al, 2006). PI3K III generates PI(3)P that regulates membrane trafficking processes via 
recruitment of a subset of proteins containing PI(3)P-binding PX (phox homology) and FYVE 
domains (Koyasu, 2003). Specific FYVE-domain proteins such as early endosomal antigen 1 
(EEA1), interact with Rab5 GTPases that control vesicle docking and fusion in the early 
endocytic pathway (Falasca & Maffucci, 2009).  Therefore, PI3K III may be important to the 
transport and sorting of proteins in the GERL pathway.  
Studies have suggested that PI3K III and I are not redundant in the GERL pathway in cells and 
may participate in different stages. It was reported that PI3K III is involved in phagosome 
formation and maturation, whereas PI3K I is required for optimal phagocytosis in human 
macrophages (Vieira et al, 2001). A reduction of PI3K III expression in human glioblastoma 
cells did not affect the normal endocytosis and protein trafficking from the TGN, but caused 
defects in the late endosomal department. These defects were manifested by enlarged 
endosomes and a reduced rate of processing and sorting of proteins to lysosomes (Johnson 
et al, 2006). Hypothetically, alteration in PI3K I and III expression may result in disruption of 
endocytic pathway, thus raising the possibility that there is defective vesicle formation, 
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reduction at 24 months. The change of MT I expression was the highest whereas MT III 
expression was the least changed amongst three (Table 5.3; 5.4; 5.5)  
5.3.1.1      MT I 
MT I showed a high basal expression of at least 100,000 copies/µl cDNA in all the control 
animals. A significant increase of expression was found as early as 6 months and was highest 
at 18 months in the affected animals. The expression in affected brains had decreased by 24 
months but remained considerably higher than that in age-matched controls (Figure 5.1A). 
Significant fold changes were found in the affected animals in comparison to their age-
matched controls. Changes of 7, 20, 30 and 13 fold in expression between genotypes were 
seen at 6, 9, 18 and 24 months respectively (Table 5.3). 
5.3.1.2      MT II 
MT II was the least abundant isoform expressed. MT II was expressed in all the control 
animals at all ages and fluctuated between ages (Fig 5.1B). A range of expression between 
6x104 and 1.1x105 copy/µl cDNA was found in the controls. MT II expression in the affected 
animals did not change until 6 months, after which it increased by 8 fold at 9 months, 11 fold 
at 18 months and 5 fold at 24 months (Table 5.4).  
5.3.1.3      MT III 
MT III expression was similar in the controls at all ages (Fig 5.1 C). MT III expression was 
elevated relative to the age-matched controls in the affected animals from 6 months to 24 
months. The up-regulation was the most significant at 9 and 18 months (P<0.01), 3 and 4 
fold respectively, and 3 fold at 6 and 24 months (P<0.05) (Table 5.5).   
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Table 5.3 Fold change of MT I expression 
Gene of Interest Age 
(months) 
Statistical 
significance* 
  
Fold change in 
comparison to age-
matched controls 
MT I 2 - - 
6 ** 7 
9 ** 20 
18 ** 32 
24 ** 13 
* -, not significantly different; *, <0.05; **, <0.01 
Table 5.4 Fold change of MT II expression 
Gene of Interest Age 
(months) 
Statistical 
significance 
 
Fold change in comparison 
to age-matched controls 
MT II 2，6 - - 
9 ** 8 
18 ** 11 
24 ** 5 
 
Table 5.5 Fold change of MT III expression 
Gene of Interest Age 
(months) 
Statistical 
significance 
  
Fold change in comparison 
to age-matched controls 
MT III 2 - - 
6 * 3 
9 ** 3 
18 ** 4 
24 * 3 
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5.3.3.2      PI3K III 
PI3K III expression was detected in all the regions of the control and affected animals. 
However, there was no disease-related change (Fig 5.4).  
5.3.3.3      pAkt-Ser473 
Activation of protein kinase B (Akt) was recognised by dual phosphorylation at Thr308 and 
Ser473, designated as pAkt-Thr308 or pAkt-Ser473. pAkt-Thr308 and the total non-
phosphorylated Akt were not investigated in these immunoblots, therefore the fraction of 
activated Akt cannot be inferred. pAkt-Ser473 showed no difference in expression between 
the control and the affected frontal and parietal regions (Fig 5.4).  
The antibody detected a faint band below the band at the expected molecular weight 
(60kDa, Fig 5.4) which has been reported to appear in some blots in the customer reviews 
published by the company (Cat#9271, Cell signalling, USA, 2015).  
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earlier in the disease than the cytokine transcriptional factors (NF-ᴋB, JAK/STAT, MAPK), the 
trend of their expression are similar to the signalling molecules investigated in the previous 
chapter. Changes in expression were not regional and were obvious at 6 months, highest at 
18 months then declined at 24 months. These results indicate a general gene up-regulation 
in the affected animals. It is not understood what could have caused this similar and 
unanticipated generalised response in the affected animals. This generalised response 
follows glial activation at 2 months and correlates with the initiation of neurodegeneration 
at 6 months of age, but is prior to clinical disease manifestation evident at 10-14 months. It 
may suggest an over-drive of cellular response following glial activation and may not be 
causative of the neuroinflammation. 
5.4.1.1      MT I and II expression in glial cells 
MT I and II expression shift regional and cellular distributions during brain development. 
During ovine brain development, the expression is initially localised to the cells of the 
proliferating ventricular zones, subsequently becoming cell-specific and predominantly 
localised to radial glial cells, oligodendrocytes and astrocytes in the cerebral cortex. Finally 
the expression is exclusively found in astrocytes in the cerebral cortex, pia mater, and the 
choroid plexus in adult ovine brains (Holloway et al, 1997; Dincer et al, 1999). Similar MT I/II 
expression is reported in human brains (Blaauwgeers et al, 1993).  
The up-regulation of MTs I and II has been associated with reactive astrogliosis around the 
injured sites in the brain, and amyloid plaque in AD (Hidalgo et al, 2001; Carrasco et al, 2006; 
Chung et al, 2004; 2008). The chronic and gradual up-regulation of MT I and II may correlate 
with glial activation in the CLN6 affected brain. However, the MT I and II expressions 
contrasted with the progressive and regional pattern of glial activation in that it did not 
differ between regions.  
This lack of regional expression of MT I and II suggests a generalised response, probably in 
astrocytes, to the change of cellular environment. A detailed characterisation of MT I and II 
expression in GFAP-immunoreactive cells described by Holloway et al (1997) indicated MT I 
and II expression are independent of glial activation. In this study, they showed a range of 
immunostaining intensities for MTs, from very intense to undetectable. This suggests 
expression of MTs does not necessarily associate with glial activation and is likely to be 
responsive to other localised stimuli.  
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The increased expression of MT I and II may be provoked by a change of biochemical 
environment in CLN6 affected brains. The cytokine expression profiles revealed an abnormal 
inflammatory response in all brain regions. This links to a generalised disturbance of the 
cellular environment in the CLN6 affected brains and the MT I and II expression may reflect 
such a change. 
5.4.1.2      MT I and II expression and metal toxicity 
Another hypothesis suggests that MT I and II up-regulation is caused by the disruption of 
metal homeostasis in CLN6 affected brains. Concentrations of zinc and manganese were 
shown to increase in neurodegenerative sites in the CLN6 affected ovine brain (Kanninen et 
al, 2013). Similar observations, in addition to increased concentrations of copper, iron and 
cobalt, were found in CLN1, CLN3 and CLN5 mice models (Grubman et al, 2014). The 
increased expression of MTs was thought to be associated with the increase of zinc 
concentrations and to serve a neuroprotective role (Kanninen et al, 2013). Indeed, MTs are 
involved in transport and redistribution of metals in the cells (Apostolova & Cherian, 2000; 
Ye et al, 2001; Hao et al, 2007). Cells could take up metal bound MTs from extracellular 
space via endocytosis and release metal to the lysosomes, either by binding to an acceptor,  
being sequestered by the lower pH, and/or by the strong oxidising environment of late 
endosomes/lysosomes (Jiang et al, 2000; Maret, 2004; Austin et al, 2005). The unloaded MTs 
are either subjected to degradation in the lysosome or recycle back to the plasma 
membrane (Mehra & Bremner, 1985; Hao et al, 2007). Lysosomes are involved in 
homeostasis of biometals, and the sequestration of metals into lysosomes may be a 
mechanism to avoid cytosolic toxicity (Palmer, 1987; Hao et al, 2007; Lloyd-Evans et al, 
2010). Induction of MTs could be caused partially by the increased concentrations of zinc 
and copper, as part of a protective mechanism to prevent cytosolic accumulation.  
The general up-regulation of MTs without preferential distribution between the affected 
brain regions may indicate an increased metabolic rate, to store, donate and distribute 
essential metals such as zinc. This generalised response is not likely to be caused by an 
increased metal toxicity. The investigation of the roles of biometals in ovine CLN6 revealed a 
remarkable tolerance towards the high level of metal deposition in lysosomes in the CLN6 
affected sheep (Palmer, 1987). Metals are more likely to be stored in the brain cells since 
they are post-mitotic (Palmer, 1987). There is clear evidence that the accumulation of metals 
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is endogenous and may not be as toxic as anticipated. Chronic copper poisoning only causes 
a slight elevation of brain Cu concentrations in sheep and Bedlington terriers at the 
haemolytic phase, suggesting a tight regulation of metal homeostasis at the BBB (Morgan, 
1973; Howell et al, 1974; Herrtage et al, 1987). Another study also showed the intentional 
increase of ovine brain Cu concentrations did not cause neuronal damage (Dincer, 1994). 
Moreover, measurements of the metal contents in the CSF in the CLN6 affected brain did 
not reveal changes (Palmer, 1987). Thus, the higher concentration of metals may possibly 
arise from a high metabolic rate of the CLN6 affected brain cells and not from the disruption 
of metal homeostasis.  
5.4.1.3      MT III expression and zinc buffering 
MT III is a brain-specific protein specialising in sequestration and storage of zinc in neurons 
(Masters et al, 1994; Ebadi et al, 1995). A few reports demonstrated elevated expression of 
MT III mRNA and protein in subsets of astrocytes upon neuronal insult (Carrasco et al, 2000; 
Hozumi et al, 2008; Lee et al, 2010). It is difficult to interpret the expression profiles of MT 
III. If MT III were expressed strictly in neurons, expression may have been underestimated 
due to the neuronal degeneration, leading to proportionally fewer neurons in the overall cell 
population, hence diluted concentrations of MT III in the degenerated brains. The expression 
of MT III did not show a significant change at 2 months, when neuroinflammation is 
activated, indicating that the up-regulation of MT III is not a primary response correlating 
with glial activation.  
Zinc is known to be involved in neurotransmission and neuromodulation, via interaction with 
neuronal ion channels, receptors and transporters (Cuajungco & Lees, 1997; Sensi et al, 
2009). Changes of cellular composition due to neurodegeneration could alter the 
concentration of zinc. The expression pattern of MT III in the affected brains did not differ 
between regions and was similar to other MTs, showing MT III up-regulation is more likely to 
be attributed to a widespread up-regulation in response to glial activation.  
Moreover, studies have shown that MT III expression may only play a minor role in the 
regulation of biologically active zinc. Reduction of MT III was found in AD patients and was 
thought to contribute to the pathophysiology of AD (Uchida et al, 1991; Tsuji et al, 1992). 
Mice with either an over-expression of MT III or a deficiency of MT III showed normal 
physiology and a lack of AD-like pathophysiology in spite of changes of zinc concentrations, 
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mutations underly a new form of NCL. Moreover, accumulation of autofluorescent lipofuscin 
is not an accurate phenomenon for describing the characteristic of storage bodies, which are 
mainly composed of protein aggregates (Palmer et al, 1986a, 1986b, 1989; Jolly et al, 1988; 
Palmer et al, 1992; 2013; 2015; Tyynela et al, 1993; Palmer et al, 1997; Palmer et al, 2002; 
Chen et al, 2004; Palmer, 2015). This characteristic is particularly important as an indication 
of the biochemical nature of NCL disease. One study seemingly confirmed the 
neurobiochemistry of GRN-/- mice is NCL-like, based on the apparent similar pathological 
proteins profile between Ctsd deficient mice and GRN deficient mice, (Gӧtzl et al, 2014), but 
the characterisation of the protein profile does not relate to lysosomal derived organelles 
(e.g. subunit c). 
The same study also found similar proteins stored in NCL and FTLD patients (Gӧtzl et al, 
2014). The correlation between the two diseases was then made. In the study, the human 
brain extract of NCL patients appeared to have increased amounts of proteins, such as TDP-
43, which are associated with FTLD-TDP/GRN. In FTLD-TDP/GRN patients, there was a slight 
increase of saposin D (sphingolipid-activator protein D, SAP D). A few concerns are raised. 
Firstly, the genetic mutations were dubious in the NCL patients, with only CLN2 identified 
and the other NCLs were recorded as juvenile and adult NCL. Juvenile and adult NCL could be 
caused by many NCL genes since NCL has the characteristic of genetic heterogeneity. For 
instance, CLN6 NCL is reported to cause late infantile and adult forms of NCL (Kousi et al, 
2011). Secondly, the study had used the brain extract from juvenile NCL patients (CLN3) and 
CLN2 patients. The main lysosomal storage materials are subunit c of mitochondrial ATP 
synthase in CLN2 and CLN3 (Kousi et al, 2011). Therefore, saposin D is not an accurate 
marker for proteinopathy for CLN2 and CLN3. Thirdly, and importantly, the protein extracts 
used for analyses in the study were not derived from the storage bodies. Lastly, TDP-43, 
shown to accumulate in NCLs and FTLD-TDP/GRN patients, has also been reported to 
accumulate in ALS patients without SOD1 mutations as well as in aged human brains 
(Neumann et al, 2006; Mackenzie et al, 2007; Yu et al, 2015).  
The up-regulation of multiple genes at the terminal disease in the present study indicates a 
general metabolic overdrive in CLN6 disease. Certainly this is expected as the balance of cell 
type changes radically because of neurodegeneration. Therefore, potentially, a range of 
protein expressions could be increased in the late disease and such increases in protein 
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Other hypothese followed to suggest the genetic mutation leads to disruption in lysosomal 
function, autophagy and mitochondrial turnover and degradation, and in turn to the 
accumulation of the storage bodies (Seehafer & Pearce, 2006). These were thought to cause 
further cellular disturbances, which subsequently aggravates the cumulative process in 
lysosomes and increases the oxidative stress in lysosomes. The oxidative stress was thought 
to be facilitated by the presence of transitional metals in lysosomes and to cause 
mitochondrial dysfunction (Brunk & Terman, 2002; Seehafer & Pearce, 2006). This scenario 
led to a number of studies in vitro to prove oxidative stress plays a role, in the context of ER 
stress (Kim et al, 2006b; Wei et al, 2008), autophagy disturbances (Vidal-Donet et al, 2013), 
mitochondrial abnormalities (Majander et al, 1995; Dawson et al, 1996; Siakotos et al, 1998) 
and lysosomal dysfunction (Prasad et al, 1996) 
The facts strongly argued against this hypothesis. The stored lipid profiles are normal in the 
storage bodies (Palmer et al, 1986a; b; 1988; 1989a; 2002; 2015). The storage bodies were 
enriched with transitional metals and the enrichment correlated with the tissue specificity of 
the metal metabolism (Palmer, 1987). The presence of metals did not facilitate lipid 
peroxidation since there was no evidence of lipid peroxidation (Palmer, 1987; Palmer et al, 
1988; Jolly et al, 2002). Moreover, the stored protein is highly specific and unique (Palmer, 
2015). In subunit c storing NCLs, storage is specific to subunit c and subunit c storage is 
specific to the NCLs, and none of the other 16 ATP synthase subunits or any other inner 
mitochondrial membrane proteins are stored (Fearnley et al, 1990; Chen et al, 2004; Palmer, 
2015). Some subunit c accumulation has also been reported in other LSDs, like Niemann-Pick 
types A and C, GM1 and 2 gangliosidoses and MPS I, II and III, but the degree of storage is 
minimal in these diseases and less uniform than in NCLs, suggesting that the accumulation of 
subunit c is especially amplified in lysosomes of neuronal and non-neuronal cells in subunit c 
storing NCLs (Elleder et al, 1997). Moreover, the accumulation of the storage bodies occurs 
in nearly all cells of NCL patients, and cells in the CNS do not degenerate equally. Some 
neurons with a heavy burden of storage bodies survive, suggesting the accumulation is not 
damaging but is a separate consequence of the genetic lesion (Palmer et al, 2002; Oswald et 
al, 2005). 
The post-translational modification of subunit c may offer some clues as to what may cause 
the abnormal turnover of subunit c. The trimethylation of lysine43 in the subunit c is 
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conserved among Metazoans and is suggested to associate with cardiolipin to facilitate 
formation of the subunit c ring structure in the inner membrane of mitochondria (Watt et al, 
2010; Walpole et al, 2015). The stored subunit c in lysosomal derived organelles is also 
trimethylated (Chen et al, 2004; Walpole et al, 2015). The abnormal subunit c storage is 
unlikely to arise from dysfunctional mitochondria. Despite the conflicting reports on 
mitochondrial dysfunction (Seehafer & Pearce, 2006), evidence showed normal 
mitochondrial activities in the CLN6 affected sheep (Palmer et al, 1992). There was also a 
lack of disease-induced mitochondrial activities as the expression of mitochondrial proteins 
(MnSOD and COX IV) were not increased in the CLN6 brain (Chapter 3). Although there is a 
lack of clear correlation between the trimethylation of the subunit c and its storage in 
lysosomes, it may be possible that the subunit c trimethylation or demethylation, mediated 
by methyltransferases (Walpole et al, 2015), may be altered in the sorting and trafficking 
pathway for subunit c and lead to pathological accumulation, in which all NCL proteins play a 
role. 
Neuroinflammation plays a central role in the neuropathology of NCLs (Palmer et al, 2013). 
That neuroinflammation preceded neurodegeneration was established in studies of the 
CLN6 sheep model. Both astrocytic and microglial activation began perinatally, spreading 
from specific foci in cortical regions associated with later neurodegeneration and symptoms 
(Oswald et al, 2005; Kay et al, 2006; 2011). Glial activation is often associated with the 
release of ROS and production of pro- and anti- inflammatory cytokines (Brown & Neher, 
2010; Glass et al, 2010). Thus, glial activation may trigger oxidative stress. The up-regulation 
of MnSOD, reported to be significant in CLN6 affected human fibroblasts and in the brains of 
CLN6 affected sheep, was thought to be associated with glial activation related oxidative 
stress and/or neuroinflammatory cytokine- regulated responses (Fridovich, 1983; Merrill & 
Benveniste, 1996; Sayre et al, 1999; Heine et al, 2003). This prompted the present study to 
observe any change of MnSOD expression in CLN6 over time, as well as a study of the 
expression of other oxidative stress related mediators, including HO-1 and iNOS (Schipper et 
al, 2009a;b ; Brown & Neher, 2010). iNOS has been proposed to be expressed in activated 
microglial cells and to be responsible for release of pathological NO (Chapter 3; Dringen, 
2005; Saha & Pahan, 2006; Pautz et al, 2010; Brown & Neher, 2010). As reported in Chapter 
3, the expression of MnSOD was not correlated with the disease development, iNOS was not 
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expressed in sheep and HO-1 expression was low. These results clearly indicate that 
oxidative stress does not contribute to the progression of the disease, nor in the mechanism 
by which cytokines induce neurodegeneration, and revealed a problem associated with 
sampling brain regions.  
Neurodegeneration and glial activation lead to major cytoarchitectural changes in the brain. 
False positive results could be produced when isolating specific isolation of brain regions for 
observation. Expression of mitochondrial proteins, MnSOD and COX IV, are typical examples 
(Chapter 3). Immunohistochemistry showed that the expression of those markers and the 
distribution of mitochondria is highly uneven (Fig 3.5; Fig 6.1). This is even more pronounced 
in the affected brains (Fig 3.5; Fig 6.1). The atrophy of the cortex in the affected animals 
resulted in a greater density of MnSOD and COX IV expressing cells in some locations, 
leading to a misconception of an increased number of such cells in these locations in the 
affected animals when observation was confined to a microscopic area (Fig 6.1). This could 
explain the conclusion that the expression of these proteins increased in a small region as 
well as the higher gene expression for MnSOD in parieto-occipital cortices at late disease 
(Heine et al, 2003; Chapter 3). However, integration of the MnSOD and COX IV expressing 
cells in the overall neurodegenerative cortices showed that the overall protein expression is 
reduced as these cells are subject to neurodegeneration. This means that sampling a small 
region randomly for a study may not represent the change of the whole brain since 
neurodegenerative events do not occur equally in all cells nor in all locations. 
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Figure 6.1  A representative figure of sampling that could be acquired for different 
experiments. 
This figure illustrates the problem associated with sampling, which is discussed in section 4.4.2.  The 
area in the blue box indicates the area that would be sampled to acquire the amount of tissue for 
used in for the RNA and protein extractions.  A heterogeneous cell population stained for MnSOD is 
distributed unevenly across the cortical layers of the control parietal cortex (left). The sampling area 
would need to be altered to compensate for the loss of cells in the affected parietal cortex (right), in 
order to match the overall cell number in control samples. Because the immunoreactive cells in the 
atrophied cortex are relatively more packed in comparison to the controls, more MnSOD mRNA 
Control  
Parietal cortex 
18 months 
CLN6 affected 
Parietal cortex 
18 months 
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could be obtained than from the control for the same amount of cells harvested. The area in the red 
box indicates the same area for microscopic observation. The similar location in the control is 
replicated in the affected, disregarding the cytoarchitectural change caused by the 
neurodegeneration in the area. This can lead to an appearance of increased MnSOD expression in 
cells, when, in fact, it is a phenomenon of compression of the cell layers that has changed the 
distribution of cells. 
 
The iNOS-centred mechanism of inflammation and oxidative stress should be discarded from 
the neuroinflammatory cascade in ovine and human NCL. Expression of iNOS has been 
largely recognised and discussed as a major driving cause of oxidative stress following 
microglial activation in rodent models (Mander & Brown, 2005) and also in many other 
published studies. However, the evidence is clear that iNOS is not expressed in sheep 
(Chapter 3), or in humans (Gross et al, 2014). This illustrates that using rodent models for 
inflammatory studies may not be ideal and the results derived from rodent models may not 
be translatable to humans. 
Meanwhile, a long term trial of therapeutic intervention by minocycline, a broad spectrum 
anti-inflammatory drug, which has activity against neuroinflammation (Kumar et al, 2003; 
Nikodemova et al, 2007), did not result in inhibition of neuroinflammation or 
neurodegeneration (Kay & Palmer, 2013). Early administration prior to the onset of 
neurodegeneration and effective drug absorption into the brain did not aid the suppression 
(Kay & Palmer, 2013). This shows that non-selective drug intervention to suppress 
neuroinflammation is not likely to succeed. High throughput drug screening methods are not 
practical in large animal models. A mechanism-based choice of drugs for inhibition may hold 
some hope in the suppression of neuroinflammation. Thus, defining the relevant 
neuroinflammatory cascade was thought more likely to provide a more accurate target and 
time-span in which therapy will be required for optimal benefit. 
The loss of neuronal populations in ovine CLN6 was characterised as progressive, selective, 
regional and cell- type specific, all well as predicted by glial activation (Oswald et al, 2005; 
2008; Kay et al, 2011). Thus it was anticipated that molecular profiles would vary between 
brain regions, and changes to these molecular cues would possibly parallel 
neuroinflammation prior to neurodegeneration in the parieto-occipital cortex (Oswald et al, 
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2005). A longitudinal molecular dissection of the neuroinflammatory cascade was initiated 
through a study of pro- and anti-inflammatory cytokines (TNF-α and IL-1β, and TGF- β and IL-
10) and their co-stimulated pathways, including a positive feedback loop which can result in 
neuronal damage (JAK/STAT, NF-κB and MAPK) and a negative feedback loop which leads to 
inhibition of pro-inflammation (SOCS3) (Chapter 4; Glass et al, 2010; Barry, 2011). Other 
positive feedback pathways that aggravate neuronal damage were investigated, including 
the loss of neurotrophic factor support due to dysfunction in the GERL pathway (BDNF and 
TrkB) and the activation of adaptive immunity that results in a breach of the BBB and entry 
of lymphocytic cells (CD4 and CD8) (Henderson et al, 2000; Kopan et al 2004; Lim et al, 2007; 
Saha et al, 2012). Other makers proposed to be involved in the pathogenesis of NCLs , 
namely, PI3K I, PI3K III, metallothioneins and progranulin were also investigated in Chapter 
5.  
An unanticipated inflammatory response was revealed. Changes in the gene expression were 
widespread in the diseased brain, contrasting with the progressive and regional involvement 
of glial activation, and there was a lack of evidence for unique disease-causative lesions. The 
gene expression of the neuroinflammatory mediators described in Chapters 4 and 5 display a 
remarkably similar trend of elevation in expression following glial activation and a sharp 
decrease in the dying brain. Additionally, the proposed transcriptional factors responsible for 
these cytokine expressions were either activated in the advanced disease (NF-ᴋB, MAPK) or 
activated moderately (STAT1 and 3) (Raivich et al, 1999; Li & Verma, 2002; Kumar et al, 
2003; Brown & Neher, 2010; Minogue et al, 2012). Only one anti-inflammatory modulator is 
actively up-regulated prior to neuroinflammation, SOCS3 (Baker et al, 2009). A disruption of 
the blood-brain barrier was discounted as there was no sign of lymphocytic infiltration in the 
brain of ovine CLN6 (Chapter 4), while roles for the pro- and anti-inflammatory cytokine 
regulated pathways remain (Figure 6.2). In general a large number of gene expressions 
change in some way with the disease, but most, if not all, are unlikely to be central to the 
disease pathogenesis.  
The changes in gene expressions are widespread in the affected CLN6 brains. In conclusion, 
the current molecular approach of dissecting of neuroinflammatory cascade did not provide 
sufficient information for selection of therapeutic targets but showed that a complicated 
neuroinflammatory network underlies the CLN6 disease. This reinforces the need for 
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understanding the neuroinflammation in a genome-wide scale using a genetic screening 
method with carefully selected regions.  
The approach of assembling “pathways”  from simple models, which focus on a few 
pathways, timepoints and/or single cell types, is simplistic. There are many weaknesses 
associated with simple disease models. High dosages of inflammatory stimuli are often 
applied to cell cultures to provoke intensive responses and the measurement are usually 
focused on a few inflammatory markers. Studies of neuroflammation on acute disease 
models, such as brain trauma or on the human tissue extracted from the end-point disease, 
represent severe biochemical responses but lack resolution since the neurodegeneration is 
chronic in nature and gradually evolves with time.  
The heterogeneity of cell populations and the distribution of the cells in different brain 
regions may lead to different survival rates. Loss of GABAergic interneurons in the ovine 
CLN6 brain displayed a contrasting pattern in different regions, emphasising that cellular 
location and interconnectivity are the major determinants of neuron survival (Oswald et al, 
2008). Subtle molecular cues may be localised, and not be detected by the current method, 
yet may contribute to the vulnerability of cells. Therefore, even though they did not show 
regional differences, subpopulations of cells and other determining factors may make them 
more vulnerable to inflammatory-induced decline (Barry, 2011). Hopefully, the genetic 
screening method is able to provide some insights into these determining factors. 
The CNS is a hierarchically organised complex system, divided into brain regions, cell types, 
organelles and molecular pathways. A systemic network approach would allow intergration 
of multi-level information, such as transcriptomic and proteomics, to identify causal 
molecular drivers of cellular, circuit-level and brain-wide pathology in disease (Parikshak et 
al, 2015). Methods such as RNA-sequencing is able to quantify levels of transcripts and their 
isoforms in a biological sample, which could be specific cells or tissue, at a specific 
develomental stage or physiological condition (Section 6.1.1.1; Wang et al, 2009). A 
preliminary study using RNA-sequencing conducted on the CLN6 affected Merino and 
control sheep showed it is possible use in the study of disease mechanisms in the NCLs 
(Chang et al, 2014). Preliminary gene ontology analysis associated differential gene 
expression patterns with the induction of inflammation, cell surface receptor linked signal 
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transduction, cellular and metal ion transport, tissue remodelling (activation and inactivation 
of genes associated with actin, myotubules, cell-adhesion) and apoptosis (Chang et al, 2014). 
The results highlight the diverse molecular changes accompanying neurodegeneration. The 
costs associated for using such technology have become much lower than previously and the 
technologies are now readily accessible. Future studies could use high read depth RNA-Seq 
analyses in ovine NCL models to develop a better understanding of the pathogenic cascade 
in different NCL variants and for multiple tissue comparisons, and to evaluate the effects of 
gene therapy agents. 
On a separate notion, the weaknesses of determining  a disease phenotype without an 
thorough understanding of the biochemical lesions was discussed in Chapter 5. Although the 
genotype and phenotype correlations in NCLs are not clear, the classical forms of NCLs 
(CLN1, 2, 3, 5, 6, 7, 8 and 10) have uniform pathological features, particularly the storage of 
specific proteins, either subunit c of mitochondrial ATP synthase or sphingolipid-activator 
proteins A and D (SAP A and D). These abnormal storage materials are not a result of a 
general metabolic disruption in the GERL pathway. For example,  PI3K I and PI3K III were not 
altered and BDNF and Trk B did not play roles in disease development (Chapters 4 and 5), 
suggesting the general endocytic pathways is not disrupted in early CLN6 disease. Thus, the 
specificity and uniqueness of the protein storage suggest mutations of classical NCL genes, 
which may be categorised as the subunit c storing type or the SAP A and D storing type, 
arising from pertubations of a common and specific biochemical pathway in which NCL 
proteins may interact. For instance, CLN5 has been suggested to interact with CLN3 in SH-
SY5Y human neuroblastoma cells in a quantitative proteomics study (Scifo et al, 2013). 
Although the idea that the NCL proteins lie on the common pathway is an assumption, it at 
least presents a collective identity that unites NCLs. More recently proposed NCL forms lack 
such bichemical characterisation.  The expression of the progranulin gene (GRN) was not 
altered presymptomatically in the ovine CLN6 brain (Chapter 5). This reduces the possibility 
of progranulin having a common association with NCLs. The study which characterised the 
pathobiochemical features shared between NCLs and FTLD (Gӧtzl et al, 2014), was largely 
based on inappropriate methods due to a lack of understanding of biochemical pathology of 
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Streib & Glazko, 2011; Khatri et al, 2012). These pathways can then be ranked according to 
the number of genes in the pathway that are differentially expressed (Kavanagh et al, 2013). 
The results may enable further functional inferences and relevant studies to be developed. 
However, analysis of the significance of the pathway needs to be considered since some 
genes may play roles in networks affecting multiple pathways (Kavanagh et al, 2013).  
Single cell transcriptomics are also available (Kanter & Kalisky, 2015). The technique would 
help to identify and characterise molecular profiles in specific cell types and allow a better 
understanding of a particular cell response under the disease influence. The method may 
detect changes of gene expression that are unique and disease-associated but masked by 
the “bulk” tissue analysis (Kanter & Kalisky, 2015). Laser-capture microdissection could be 
adapted to isolate specific cells of interest from microscopic regions of tissue that could later 
be subject to RNA-Seq for characterisation. This method is particularly useful for complex 
and heterogeneous tissue (Emmert-Buck et al, 1996; Hodges et al, 2006).  
6.2.5.2      Proteomics of signalling molecules 
The signalling transduction system relies greatly on the half-lives of the proteins and of the 
post-translational modification, especially phosphorylation. Thus, the maintenance of 
signalling transduction may rely on the half-lives of the signalling molecule and detecting the 
activation of a signalling pathway requires detection of the post-translationally modified 
transducers.  
Protein and mRNA synthesis, mRNA transcription and translation, protein and mRNA 
degradation may all be regulated co-ordinately to deliver either stable or transient 
production, and amplification of the protein (section 4.5.7). The correlation between protein 
expression and mRNA expression seems to be reflected in the half-life of a protein. For 
instance, short-lived protein expression, such as for signalling molecules, correlates tightly 
with mRNA expression (Wang et al, 2002b; Yang et al, 2003; Raj et al, 2006; Sharova et al, 
2009; Dey et al, 2015). On the other hand, the transient activation of a signalling pathway 
could occur in the absence of an increase of mRNA transcripts. The signalling molecules 
investigated in the present study were mainly determined at the transcriptional level and 
may represent a chronic activation of transcriptional pathways but not temporal or transient 
activation. For instance, the pre-existing cytosolic fraction of transcriptional factors could be 
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activated rapidly, either by phosphorylation (eg. JAK) or dissociation from an inhibitor (eg. 
NF-ᴋB). This allows an instant response and reduction of transcriptional noise (Raj & van 
Oudenaarden, 2008). Therefore, signal transduction could possibly be sustained 
independently of mRNA expression in a short-term if a protein has a relatively long half-life. 
In this case, mRNA expression may not predict the activation of the signal transduction.  
It has been found that the pattern of gene transcription is discontinuous, a phenomenon 
sometimes referred as a transcriptional burst, and the corresponding protein expression 
seems to correlate to such pattern (Chubb et al, 2006; Raj & van Oudenaarden, 2008). One 
of the proposed mechanisms for the transcriptional burst is the existence of pre-initiation 
complexes that bind to the promotor region of DNA and enable multiple rounds of RNA 
polymerase II transcription (Blake et al, 2003; 2006). This would mean that gene expression 
by transcriptional factors does not necessarily require an increased mRNA transcription of 
the transcriptional factors, but that is relies more on the stability of an mRNA molecule. 
Detection of the phosphorylation state of transcription factors, their upstream regulators or 
the downstream substrates by Western blotting is more appropriate than detection of 
mRNA expression. For instance, activation of JAK/STAT3 could be detected by the expression 
of phospho- STAT3 (Tyr 705). This would avoid the uncertainty of the mRNA-protein 
expression correlation and could be used to validate the results generated from 
transcriptomics. However, the function of signalling molecules can be pleiotropic. For 
example, the cause and function of the sole elevation of SOCS3 prior to neuroinflammation 
and neurodegeneration are not understood when its known activator, IL-10, and 
transcription factor (STAT3) were not elevated until later in the disease progression (Chapter 
4; Yasukawa et al, 2003; O’Shea & Murray, 2008; Qin et al, 2008; Baker et al, 2009). The anti-
inflammatory role of SOCS3 is also ambiguous. It has been proposed to have an anti-
inflammatory role, but it clearly did not supress neuroinflammation in this study despite its 
statistically significant up-regulation. IL-6 is known as an inflammatory cytokine. SOCS3 plays 
a role in the self-inhibiting mechanism of IL-6 signalling, in which SOCS3 expression is 
induced by IL-6-STAT3 activation to dampen the inflammatory action of IL-6, via SOCS3 
binding to the tyrosine 757 of the IL-6 receptor/gp130. Sustaining STAT3 activation in 
addition to deletion of the SOCS3 binding site on IL-6 receptor (gp130) demonstrated an 
anti-inflammatory action of IL-6 identical to that of IL-10 (Yasukawa et al 2003; El Kasmi et al, 
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2006). In this case, SOCS3 seems to be pro-inflammatory, suggesting that SOCS3 could play 
pleiotropic roles in neuroinflammation. Thus, evidence of the activation of one gene could 
be insufficient to predict the biochemical consequence of that gene. Quantitative proteomic 
analysis of phosphorylated proteins may improve the understanding of the signalling 
network.  
6.2.5.3      Comparison between South Hampshire and Merino ovine CLN6 and Borderdale 
CLN5 
Different CLN6 mutations occurred naturally in Merino and South Hampshire sheep. The 
mutation in CLN6 in South Hampshire comprises a 402bp deletion and a 1bp insertion that 
includes the 83bp sequence of the complete first exon; whereas a different mutation 
(c.184C>T in exon 2) in CLN6 in the affected Merino sheep causes a major amino acid 
exchange (p.Arg62Cys) (Section 1.5). Ovine CLN5 disease in Borderdale sheep has also been 
well characterised (Jolly et al, 2002; Frugier et al, 2008). The disease-causing mutation is a 
substitution at a consensus splice site (c.571+1G>A), leading to the excision of exon 3 and a 
truncated putative CLN5 protein (Frugier et al, 2008). Comparative studies of the 
neuropathology in CLN6 in Merino and South Hampshire sheep and CLN5 in Borderdales are 
underway and the comparisons between these different ovine models will follow.  
The clinical signs and neuropathology reported are remarkably similar in all these affected 
sheep in spite of the differences in the mutation types and genes (Jolly et al, 1982; 1989, 
Mayhew et al, 1985, Cook et al, 2002; Jolly et al, 2002; Oswald et al; 2005; Tammen et al, 
2006; Kay et al, 2006; Frugier et al, 2008; Palmer et al, 2015). These affected sheep exhibit 
clinical symptoms including behavioural changes, blindness and motor deficits. Subunit c of 
ATP synthase specifically accumulates in most cells in most tissues in both CLN5 and CLN6 
NCL, and many other forms (Section 1.4.1; Palmer, 2015). Brain atrophy accompanies 
neurodegeneration and neuroinflammation in these affected sheep. The disease with ovine 
models of CLN5 and CLN6 resemble the human diseases. In fact, remarkably uniform 
pathological features are also shared between forms of NCLs and the predicted location of 
NCL proteins in the GERL pathway (Palmer et al, 1986b; 1989; 1992; Fearnley et al, 1990; 
Cooper et al, 1999; Oswald et al, 2005; 2008; Pontikis et al, 2004; Bible et al, 2004; Kay et al, 
2006; 2011; von Schantz et al, 2009; Schmiedt et al, 2012) suggesting a common pathogenic 
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pathway contributes to all NCLs. Thus, the study of ovine models could provide some 
insights into pathogenesis in all NCL forms in animals and humans.  
6.3 Conclusion 
The observed neuropathology of human NCL represents the end result of a cascade of 
events.  A dissection of the molecular cascade in this longitudinal study aimed to provide a 
more accurate target and time-span in which therapy will be more likely to be effective. The 
neuroinflammatory gene expression profiles in the ovine CLN6 affected brains presented 
here revealed a widespread up-regulation of genes following neuroinflammation and 
discounted oxidative stress as part of the disease mechanism. Cytokine-mediated 
neuroinflammation remains and SOCS3 was the only molecule found to be significantly up-
regulated prior to neurodegeneration and concurrent to the glial activation. However, the 
regulatory role of SOCS3 is not understood. These results indicate that a complex signalling 
network underlies a primary defect in the NCLs. In addition, correct sampling of a targeted 
region for study is important as neurodegeneration and glial activation can change the 
cytoarchitecture and this change could differ in cell types and brain regions. Studies of 
underlying molecular cascades by transcriptomics with carefully selected target regions in 
ovine models would be beneficial for inferring the function of CLN6 and CLN5 as well as 
understanding their impact on the biochemistry in the brain. Hopefully, the study could be 
translated into human disease, and will benefit the understanding of the pathogenic cascade 
in different NCL variants and also the correlation between different NCL genes that may 
likely converge in the same biochemical pathway. Moreover, a better understanding of the 
pathogenic cascades can provide possible targets for therapeutic intervention to ameliorate 
disease. 
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Postscript 
This postscript describes some additional experiments performed after the completion of 
this thesis. MnSOD expression was determined by immunohistochemistry of sagittal CLN6 
affected brain sections and matched controls over the span of disease development, 2, 6, 9, 
18 and 24 months. Adjacent sections were immunostained for COX IV.  The results are to 
strengthen the argument discussed in chapter 3 with oxidative stress is not likely to play a 
major role in disease mechanism, based on a lack of activation of oxidative stress markers 
throughout the disease progression. The immunostaining for MnSOD and the mitochondrial 
marker, COX IV, showed paralleled staining in all the brain regions and revealed a regionally 
specific reduction in cerebral cortex. Severe neurodegeneration leads to a dramatic change 
in the cytoarchitecture of cortical grey matters, causing MnSOD and COX IV immunoreactive 
cells, which are distributed across the cortical layers II-VI, to compress to form two layers at 
the boundaries between layers I and II and between layers IV and V in the affected cortices 
at both 18 and 24 months. This phenomenon was not observed in non-degenerative brain 
regions. It was a consistent observation in the animals and a statistical analyses support the 
observation. A larger sample size was included for immunohistochemical experiment (n=3) 
and the immunostaining of MnSOD and COX IV in different cortical regions was quantified 
and analysed. Statistical analyses confirmed the observation found in this thesis and the 
results presented in this postscript and the thesis have been combined for publication.  
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Figure 1 Quantitation of immunoreactivity of MnSOD and COX IV in different brain 
regions. Thresholding image analysis of immunostaining in the cortical grey 
matter layer II-VI in different brain regions. Results are the means of at least 3 
cortical collumns from each region and expressed as the % of pixels of 
digitalized microscopic images that stained above a threshold intensity, 
vertical bars represent the standard error of the mean. *, significant difference 
(P < 0.05; paired t-test); **, highly significant difference (P < 0.01; paired t-test). 
 
18 months 24 months 
18 months 24 months 
  
 
 
 
187 
Table 1  Proportional decrease of MnSOD and COX IV immunostaining in the CLN6 
affected cortical layers II-VI at 18 and 24 months. Quantitative 
immunostaining are presented as % of immunostaining in comparison to the 
matched control regions (n=3).  
Proteins MnSOD COX IV 
Age/Brain Regions 18m SEM 24m  SEM 18m SEM 24m SEM 
Frontal cortex 75 11 69 14 76 41 74 7 
Parietal cortex 54 11 39 7 56 15 37 4 
Occipital cortex 60 12 33 5 63 35 30 
 
3 
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Figure 2 Quantitation of immunoreactivity of MnSOD and COX IV in cortices. This is 
the combined data from the three regions (frontal, parietal, occipital). 
Thresholding image analysis of immunostaining in cortical layers II-VI in brain 
regions. Results are the means of sampled cortical collumns and expressed as 
the % of pixels of digitalized microscopic images that stained above a 
threshold intensity, vertical bars represent the standard error of the mean. *, 
significant difference (P < 0.05; paired t-test); **, highly significant difference (P < 
0.01; paired t-test). 
 
 
18 months 24 months 
** 
** 
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Table 2 Proportional decrease of MnSOD and COX IV immunostaining in the CLN6 
affected cortical layers II-VI at 18 and 24 months. This is the combined data 
from three regions. Quantitative immunostaining are presented as % of 
immunostaining in comparison to the controls (n=3). 
Proteins MnSOD COX IV 
Age/Brain Regions 18m SEM 24m  SEM 18m SEM 24m SEM 
Affected cortex 63 6 52 7 66 11 52 8 
 
 
 
Table 3 Ratio of the proportional decrease of immunostaining area between MnSOD 
and COX IV in the CLN6 affected cortical layers II-VI at 18 and 24 months 
(n=3). The ratios indicate a correlated reduction of mitochondria and MnSOD 
expression. 
 
 MnSOD/COX IV at 18 
months 
MnSOD/COX IV at 24 
months 
Frontal Cortex 0.99 0.93 
Parietal Cortex 0.96 1.05 
Occipital Cortex 0.95 1.1 
Whole Cortex 0.97 1 
SEM 0.008 0.036 
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Appendix A 
1 Gel electrophoresis and Western blotting reagents 
15% Resolving Gel: 1.9ml 40% acrylamide: bisacrylamide (29:1 w/w) 
1.25ml 1.5M Tris pH 8.8 
50μl 10% LDS 
1.8ml H2O¹ 
25μl 10% ammonium persulphate (APS, Pharmacia Biotech, Uppsala, Sweden) 
2.5μl Tetramethylethylenediamine (TEMED, BDH) 
4% Stacking Gel: 0.25ml 40% acrylamide: bisacrylamide (29:1 w/w) 
0.63ml 0.5M Tris pH6.8 
25μl 10% LDS 
1.6ml H2O¹ 
12.5μl 10% APS 
2.5μl TEMED 
Electrophoresis Buffer: 25mM Tris 
192mM glycine 
0.1% LDS 
Transfer Buffer: 25mM Tris 
192mM glycine 
20% methanol 
 
2 10 X TBE 
54g Tris base 
27.5g Boric acid 
20ml 0.5M EDTA pH 8.0 
In 1L total H2O¹ 
 
3 SOC medium 
2g Bacto-tryptone 
0.5g Yeast extract 
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1ml 1M NaCl 
0.25ml 1M KCl 
In 97mls H2O¹ 
Autoclaved and cooled to RT 
1ml sterilised 2M Mg2+ stock 
1ml sterilised 2M glucose 
Up to 100ml with H2O¹, pH 7.0 
 
4 LB agar 
10g NaCl 
10g Tryptone 
5g Yeast extract 
20g Agar 
Up to 1L with H2O¹, pH 7.0 
Autoclave 
 
5 LB broth + ampicillin 
5g NaCl 
10g Tryptone 
5g Yeast extract 
Up to 1L with H2O¹, pH 7.0 
Autoclave 
100μg/ml Ampicillin 
 
 
 
1 Water deionised by electrodeionization was used for all experiments described in this 
thesis. 
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